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Abstract  
Contributions of the pore-forming toxin Listeriolysin O to Listeria monocytogenes pathogenesis 
and immunity 
By Brittney Nhu-Chau Nguyen 
Doctor of Philosophy in Microbiology 
University of California, Berkeley 
Professor Daniel A. Portnoy, Chair 
Listeriolysin O (LLO) is an essential determinant of Listeria monocytogenes pathogenesis 
that mediates the escape of L. monocytogenes from host cell vacuoles, thereby allowing 
replication in the cytosol without causing appreciable cell death. As a member of the cholesterol-
dependent cytolysin (CDC) family of pore-forming toxins, LLO is unique in that it is secreted by 
a facultative intracellular pathogen, whereas all other CDCs are produced by pathogens that are 
largely extracellular. Deletion of the gene encoding LLO, hly, or replacement of LLO with other 
CDCs results in strains that are 10,000-fold less virulent during mouse infections. Deletion of 
LLO also results in a strain that is immunosuppressive in mice. LLO has structural and 
regulatory features that allow it to function intracellularly without causing cell death, most of 
which map to a unique N-terminal region of LLO referred to as the PEST-like sequence. Yet, 
while LLO has unique properties required for its intracellular site of action, extracellular LLO, 
like other CDCs, affects cells in myriad ways. Because all CDCs form pores in cholesterol-
containing membranes that lead to rapid Ca2+ influx and K+ efflux, they consequently trigger a 
wide range of host cell responses, including MAPK activation, histone modification, and 
caspase-1 activation. There is no debate that extracellular LLO, like all other CDCs, can 
stimulate multiple cellular activities, but the primary question we wish to address is whether 
LLO secreted in the cytosol has an impact on pathogenesis.   
To address whether LLO secreted in the cytosol impacts the pathogenesis of L. 
monocytogenes we engineered a strain, referred to as hlyfl, that deletes hly after escape from 
phagocytic vacuoles. Using hlyfl, we determined that LLO secreted in the cytosol causes 
cytotoxicity that impairs the growth of L. monocytogenes in macrophages. However, this strain 
was less virulent in mice than WT L. monocytogenes because it had a defect in cell-to-cell 
spread. Furthermore, the strain was not as effective at inducing protective immunity in mice as a 
strain that was defective in cell-to-cell spread due to a defect in actin-based motility. We 
hypothesized that hlyfl was not as effective at inducing protective immunity because, like LLO-
deficient strains, it induced IL-10. Administration of anti-IL-10 receptor blocking antibody 
improved the protective capacity of vaccination with hlyfl, indicating that bacterial localization in 
primary and secondary vacuoles leads to the induction of IL-10, which is immunosuppressive.  
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To determine the bacterial components that lead to the induction of IL-10 by bacteria that 
cannot escape phagocytic vacuoles, we performed a genetic screen of transposon mutants for 
their ability to induce enhanced or diminished IL-10 from infected bone marrow-derived 
macrophages. We identified bacterial lipoproteins, which are recognized by TLR2, as the 
primary signal for IL-10 induction in macrophages. However, bacterial mutants that had 
increased lysis induced enhanced IL-10, which was dependent on signaling of endosomal TLRs. 
In mice, IL-10 induction and immune suppression was primarily mediated by endosomal TLRs. 
In summary, though LLO may cause some cytotoxicity it is absolutely required for escape from 
primary and secondary vacuoles. LLO-deficient mutants are avirulent, and they also lyse in 
vacuoles and induce expression of IL-10, which is immunosuppressive.  
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Listeriolysin O: Swiss Army knife or phagosome-specific lysin? 
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1.1 Introduction to Listeria monocytogenes 
L. monocytogenes is a Gram-positive bacterium that is ubiquitous in the environment but can 
become a facultative intracellular pathogen upon ingestion of Listeria-contaminated foods (1). L. 
monocytogenes primarily affects immunocompromised individuals, including pregnant women 
and the elderly. Furthermore, infection with L. monocytogenes leads to the induction of a robust 
adaptive immune response that is protective against subsequent infections. As L. monocytogenes 
is a genetically-tractable organism that is easily manipulated in laboratory environments, it has 
become a model for intracellular bacterial pathogens. Additionally, many are trying to take 
advantage of the immune responses induced by L. monocytogenes to develop live Listeria-based 
anti-cancer vaccines.  
specifically replicates in the cytosol of host cells. In order to reach the host cell cytosol, L. 
monocytogenes must first escape from the phagocytic entry vacuole, which requires the secreted 
cholesterol-dependent cytolysin Listeriolysin O (LLO) (2,3). In the cytosol, L. monocytogenes 
replicates and produces an actin-nucleation factor (ActA) to move intracellularly and form 
protrusions that are engulfed by neighboring cells and resolved into double-membraned 
vacuoles. Again, LLO is required for escape from these secondary vacuoles (4,5).  
1.2 Introduction to Cholesterol-Dependent Cytolysins 
Cholesterol-dependent cytolysins (CDCs) represent the largest family of pore-forming 
toxins (PFTs) and the subset of PFTs that form the largest pores (6). To date, more than 50 CDCs 
have been identified in Firmicutes, Actinobacteria, and most recently in Proteobacteria (7,8). 
With the exception of those produced by Proteobacteria, CDCs are produced by primary and 
opportunistic Gram-positive pathogens, and many have important roles in pathogenesis. Among 
CDCs that have demonstrated contributions to pathogenesis are perfringolysin (PFO) of 
Clostridium perfringens, pneumolysin (PLY) of Streptococcus pneumoniae, streptolysin O 
(SLO) of Streptococcus pyogenes, anthrolysin (ALO) of Bacillus anthracis, and listeriolysin O 
(LLO) of Listeria monocytogenes. LLO is distinct in that it is the only CDC produced by an 
intracellular pathogen and has specialized features that make it suitable for its intracellular 
localization.  
The hallmarks of CDCs are their requirement of membrane cholesterol for pore-forming 
activity, and their extremely large pores—which can be 30 - 40 nm in diameter (9,10). CDCs 
also contain a singular conserved cysteine that makes them highly sensitive to oxidation; CDCs 
were once classified as ‘thiol-activated (oxygen-sensitive) cytolysins’ because they required 
reducing agents for maximal activity (11,12). 
CDCs are secreted via a Sec-dependent pathway as monomers 50-70 kDa in mass and 
consist of four distinct domains. Secreted monomers bind to cell membranes and oligomerize 
into arc and ring prepore assemblies, which may contain up to 50 subunits. Following membrane 
binding, α-helical regions in domain 3 of each monomer refold into two β-hairpins that insert 
into the membrane and form a β-barrel pore (10,13,14). Domain 4 contains the signature 
undecapeptide sequence (ECTGLAWEWWR) that is the most highly conserved region in the 
primary CDC sequence and is required for coupling of cholesterol binding to domain 3 
rearrangement (15). The cholesterol recognition/binding motif, which consists of a threonine-
leucine pair, is also located in domain 4 (16). Both incomplete ring oligomers (arcs or slits) and 
complete rings perforate cell membranes, though pores formed by arcs are considerably smaller 
and may only function as ion channels, while rings allow the translocation of fully folded 
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proteins (17). There is evidence that CDCs translocate proteins in vivo, thereby acting 
analogously to type III secretion systems or the β-subunits of other secreted toxins (18).   
Although cholesterol is required for CDC activity and is generally considered the CDC 
receptor, a number of CDCs use human CD59 as a receptor and consequently have increased 
specificity for human cell membranes. However, these CDCs still require cholesterol for pore 
formation. These include intermedilysin (ILY) of Streptococcus intermedius, vaginolysin (VLY) 
of Gardnerella vaginalis, and lectinolysin (LLY) of Streptococcus mitis. The use of CD59 as a 
receptor may be attributed to a proline residue in place of a tryptophan in the undecapeptide (19). 
Additionally, CDCs also have conserved lectin-binding properties (20). Using glycan array 
analysis, it was shown that PLY and SLO had affinities for different glycan structures and that 
binding these glycans altered the hemolytic activity of these toxins. Like cholesterol, the 
functional domain responsible for glycan binding is domain 4. While glycan binding has not yet 
been reported for LLO, many of the modeled carbohydrate binding sites within domain 4 are 
conserved between LLO and CDCs from extracellular pathogens. Future experiments should 
investigate the roles of glycosylation with respect to cellular tropism and pathogen lifestyle. 
Although the structure and mechanism of pore formation of CDCs are largely conserved, 
several CDCs have variations in their structure that contribute to changes in function. SLO has 
60 amino acids at its N-terminus that mediate specific translocation of NAD+ glycohydrolase 
(SPN) into keratinocytes (18). Translocation of SPN induces cell death, following depletion of 
cellular NAD+, and significantly increases the virulence of S. pyogenes (21,22). PLY lacks a 
signal peptide and may be released by cell lysis or by another export mechanism (23). PLY also 
localizes to the cell wall, and its cell wall localization is dependent on SecY2A2, an accessory 
Sec system (24). LLO has a 26-amino acid addition (known as the PEST-like sequence) near its 
N-terminus that reduces intracellular toxicity, allowing L. monocytogenes to escape phagocytic 
vacuoles and survive intracellularly (25). The role of the LLO PEST-like sequence in 
pathogenesis will be discussed in depth below. 
1.3 Cellular Responses to CDC-Mediated Pore Formation 
CDCs can induce a wide range of effects in cells, including activation of membrane damage 
responses and alteration of immune cell function. Among other things, CDCs can activate 
MAPKs, caspase-1, and TLR4, modulate SUMOylation, induce mitochondrial fragmentation, 
and enhance bacterial internalization (26–28). These responses are usually common to membrane 
insult by a range of PFTs and are often the direct result of Ca2+ influx and/or K+ efflux. As a 
result of these numerous and diverse effects, LLO has been called the ‘Swiss-army knife of 
Listeria’ (Hamon, Ribet, Stavru, & Cossart, 2012; Osborne & Brumell, 2017). However, the role 
of these cellular responses in pathogenesis is not clear.  
For more details on cellular responses to pore formation, refer to the following references: 
Cajnko et al., 2014, Cassidy & O’Riordan, 2013, Seveau, 2014, and Gonzalez, Bischofberger, 
Pernot, van der Goot, & Frêche, 2008.  
1.3.1 Mitogen-activated Protein Kinase (MAPK) activation 
MAPKs are involved in the initiation of signaling cascades that activate cellular responses to 
many stimuli. Cell membrane damage by PFTs causes the rapid efflux of intracellular K+, and 
activation of the MAP kinases p38, extracellular signal-regulated kinase (ERK), Jun N-terminal 
kinase (JNK), mitogen- and stress-activated kinase 1 and 2 (MSK1/2), and cAMP response-
element binding protein (CREB). Activation of p38 and ERK are required for recovery of 
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intracellular K+ levels following treatment of cells with sublytic concentrations of LLO and 
aerolysin, a non-CDC PFT that forms 2 nm pores (Cabezas et al., 2017; Gonzalez et al., 2011).  
In Caenorhabditis elegans, p38 and JNK MAPK pathways, and importantly one downstream 
target, activator protein 1 (AP-1), provide protection against PFT toxicity (34). Thus, the 
restoration of ion homeostasis is one effect of MAPK activation in response to membrane 
perforation by PFTs.  
1.3.2 Histone Modification 
Histone modification has been observed in response to multiple pathogens and their CDCs. 
L. monocytogenes infection causes phosphorylation or dephosphorylation of Ser10 in histone H3 
and acetylation or deacetylation of histone H4, depending on the experimental conditions 
(Hamon et al., 2007; Schmeck et al., 2005). In human umbilical vein endothelial cells, L. 
monocytogenes infection caused phosphorylation of Ser10 in histone H3, leading to increased 
expression of numerous cytokines in a p38 MAPK-dependent manner (36). Conversely, in 
human cervical epithelial cells (HeLa cells), L. monocytogenes infection or LLO alone caused 
dephosphorylation of Ser10 in histone H3, deacetylation of histone H4, and transcriptional 
repression of cxcl2, a cytokine involved in inflammation and neutrophil chemotaxis (Hamon et 
al., 2007). Treatment of HeLa cells with aerolysin, PFO, and PLY also results in 
dephosphorylation of Ser10 in histone H3, and dephosphorylation is dependent on K+ efflux 
(Hamon & Cossart, 2011). Part of the Pseudomonas aeruginosa Type III secretion system, the 
PopB-PopD translocon, can form 4 nm pores on cell membranes that also result in K+ efflux-
dependent dephosphorylation of Ser10 in histone H3 in HeLa cells (38). Thus, K+ efflux 
resulting from membrane pore formation may have the ability to alter transcriptional profiles in 
ways that affect inflammation, although a role in vivo has not been demonstrated.  
1.3.3 Alteration of Mitochondrial Dynamics 
Treatment of HeLa cells with a sublytic concentration of recombinant LLO caused 
mitochondrial fragmentation, defined by breakage of the mitochondrial network into visually 
punctate structures. Mitochondria fragmentation occurred quickly after LLO treatment, and was 
transient; L. monocytogenes-infected cells completely recovered their normal mitochondrial 
network phenotype overnight, and did not become apoptotic. Mitochondrial fragmentation was 
dependent on Ca2+ influx, as cells incubated in Ca2+-free media did not undergo mitochondrial 
fragmentation upon LLO addition (39). In addition to causing histone modifications, infection of 
HeLa cells with P. aeruginosa also caused mitochondrial fragmentation, and was dependent on 
the expression of PopB and PopD (38). 
1.3.4 SUMOylation 
SUMOylation is a eukaryotic post-translational modification, similar to ubiquitylation, in 
which small ubiquitin-like modifier (SUMO) is covalently attached to proteins. Most commonly, 
SUMOylation of transcriptional regulators leads to transcriptional repression (40). Treatment of 
HeLa cells with LLO, PFO, PLY, and suilysin (SLY)—a CDC produced by Streptococcus suis—
resulted in degradation of Ubc9, an E2 SUMO enzyme, and a reduction in SUMO-conjugated 
proteins (Li, Lam, Lai, & Au, 2017; Ribet et al., 2010). Interestingly, the patterns of 
SUMOylated proteins were different for each CDC. Blockage of K+ efflux prevented LLO-
induced degradation of Ubc9, but enhanced Ubc9 degradation induced by PFO, PLY, and SLY, 
suggesting CDCs have different mechanisms for inducing Ubc9 degradation (Li et al., 2017). 
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Overexpression of SUMO 1 and SUMO 2 in HeLa cells limited infection of L. monocytogenes 2-
fold (41). Based on the observation that mice deficient for promyelocytic leukemia protein 
(PML), a known target of SUMO, had a defect in controlling L. monocytogenes, a recent study 
investigated the relationship between LLO, PML and SUMO during infection (43,44). The 
authors reported that treatment with LLO, PFO, and PLY caused deSUMOylation of PML in 
Chinese hamster ovary (CHO) cells, and that gene expression of many cytokines was reduced in 
pml-/- mouse embryonic fibroblasts (MEFs) compared to pml+/+ MEFs after L. monocytogenes 
infection, though the altered gene expression was not dependent on LLO (44). A better 
understanding of how SUMOylation affects pathogenesis can be acquired by performing studies 
in mice with conditional deletions of Ubc9 (45–47). 
1.3.5 Caspase-1 activation 
One of the hallmarks of the innate immune system is that activation of host pattern 
recognition receptors by conserved microbial products, known as pathogen-associated molecular 
patterns (PAMPs), and aberrant structure or localization of host molecules that result during 
disease, often referred to as damage-associated molecular patterns (DAMPs), leads to the 
initiation of immune responses (48–52). An example of a DAMP is extracellular ATP, which 
binds and activates P2X7, an ATP-gated ion channel. Binding of ATP to P2X7 results in K+ 
efflux and K+ efflux-dependent NLRP3 inflammasome activation (53–55). Caspase-1 cleaves 
pro-interleukin 1 beta (IL-1β) into active IL-1β downstream of NLRP3 activation, which can 
occur spontaneously in low concentrations of K+ (55,56). Many PFTs activate the NLRP3 
inflammasome, including the pore-forming component of adenylate cyclase toxin (CyaA) 
produced by Bordetella pertussis, aerolysin, SLO, LLO and tetanolysin, a CDC produced by 
Clostridium tetani (53,54,57–61). Roles for the inflammasome in the pathogenesis of B. 
pertussis, S. pneumoniae, and L. monocytogenes have been reported, although in the case of L. 
monocytogenes, excess inflammasome activation reduces virulence (61–68). 
1.4 Contributions of CDCs to Pathogenesis of Extracellular Pathogens 
Many CDCs have clear roles in pathogenesis that are often related to the recruitment of 
immune cells or disruption of tissue barriers. Though all CDCs function by forming pores on 
host membranes, there are some differences in how they contribute to pathogenesis. Differences 
in how CDCs function in vivo are likely due to differences in infection sites and the simultaneous 
effects of other bacterial factors. 
1.4.1 PFO 
Upon introduction of C. perfringens into soft tissue, often by a traumatic injury, C. 
perfringens can cause clostridial myonecrosis, a necrotic infection of muscle that is largely 
devoid of infiltrating leukocytes (69,70). Although C. perfringens produces many toxins, PFO 
(also called θ–toxin) is critical for severe pathology. PFO acts synergistically with α-toxin, a 
phospholipase produced by C. perfringens, in the development of clostridial myonecrosis (71). 
α-toxin causes most of the damage to the muscle tissue, while PFO contributes to pathology by 
inducing leukocyte aggregation in the vasculature—thereby preventing infiltration of leukocytes 
into the site of infection (72). Deletion of PFO, but not α-toxin, in a mouse muscle model 
resulted in an almost complete reduction in severe leukocyte accumulation, which was likely 
caused by the upregulation of leukocyte and endothelial cell adhesion factors (Bryant & Stevens, 
1996; Ellemor et al., 1999; Verherstraeten et al., 2015). Treatment of mice with a PFO-
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neutralizing antibody prior to infection with a lethal dose of intramuscular C. perfringens 
significantly reduced mortality (Bryant et al., 1993). Additionally, PFO is required for 
persistence of C. perfringens in a low-dose mouse femoral muscle infection model (76). 
Disruption of leukocyte migration and subsequent inflammation induced by PFO contributes to 
the disease progression of clostridial myonecrosis. 
1.4.2 PLY 
S. pneumoniae is the causative agent for a number of diseases, including pneumonia, otitis 
media, meningitis, and sepsis (77). PLY has a significant role in the pathogenesis of 
pneumococcal pneumonia and sepsis (78,79). In an intranasal mouse infection model of 
pneumonia and septicemia, mice infected with PLY-negative bacteria did not develop severe 
disease, whereas mice infected with S. pneumoniae expressing PLY were moribund within 48 
hours. Mice infected with the PLY-negative mutant had 4-logs less bacteria in both the lungs and 
blood (80). In addition, mice treated with a PLY-neutralizing antibody prior to infection with a 
lethal dose of S. pneumoniae administered intranasally or intraperitoneally had significantly 
increased survival (81,82). PLY reduced ciliary beating and caused reduced or disorganized cilia 
on the epithelial cells of human adenoid organ cultures. This result correlated with increased 
numbers of S. pneumoniae adhering to the organ cultures, mostly on damaged cells near 
disrupted tight junctions (83). Therefore, PLY may contribute to dissemination of S. pneumoniae 
during infection of the lungs by disrupting mucociliary elevator-mediated bacterial clearance and 
allowing the bacteria to invade deeper tissues through disrupted tight junctions.  
PLY-induced IL-1β secretion provides partial protection to the host during S. pneumoniae 
infections. IL-1β secretion in response to PLY is caspase-1, NLRP3, and ASC-dependent in 
many cell types (67,68,84). IL-1β-/-, caspase-1/11-/-, ASC-/- and NLRP3-/- mice had 1-log 
increased bacterial burdens compared to WT mice in a S. pneumoniae keratitis model (68). In a 
mouse lung infection model, S. pneumoniae infection caused increased lung permeability, which 
was exacerbated in mice lacking NLRP3 (66). IL-1β contributed to the activation of γδT cells, 
and their production of IL-17A. IL-17A-deficient, TCRδ-deficient, and neutrophil-depleted mice 
had significantly reduced survival compared to WT mice (67). Thus, inflammasome activation 
by PLY leads to the generation of the Th17 response, which provides some protection against S. 
pneumoniae infection. 
1.4.3 ALO 
Bacillus anthracis is capable of causing severe disease in humans after inhalation, ingestion, 
or cutaneous introduction of bacterial spores. In all cases, the disease begins as a localized 
infection that can quickly lead to sepsis (85). ALO plays a significant role in pathogenesis (86). 
Administration of 100 µg of ALO-neutralizing antibody to mice infected with a lethal 
intravenous dose of B. anthracis significantly increased survival (87). ALO is required for 
disruption of tight junctions and the gut epithelial barrier, and for the apical to basolateral 
translocation of B. anthracis across C2BBE monolayers, suggesting that the function of ALO is 
to facilitate the early establishment and penetration of B. anthracis into the gut epithelium (88). 
Though significant, the role of ALO in systemic infection is not well characterized.  
1.5 Varying Roles for CDCs in Pathogenesis 
The role of CDCs in the pathogenesis of extracellular pathogens often involves damaging, 
but not necessarily killing, cells in and around the site of infection. CDCs cause cell remodeling, 
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such as ciliary rearrangement, which may promote bacterial adhesion; they can disrupt tight 
junctions, facilitating bacterial translocation through epithelial and endothelial barriers and thus 
facilitating dissemination; and they can alter the expression of adherence factors, which can lead 
to recruitment of phagocytes and inflammation, or prevention of immune cell infiltration. 
Though many of these functions do not result in cell death, host cell lysis can also be a survival 
strategy for extracellular pathogens. Indeed, both C. perfringens and B. anthracis use their CDC 
to lyse host cells subsequent to phagocytosis, thereby releasing the bacteria back into the 
extracellular space and promoting bacterial growth (76,89). Cell lysis may also provide 
extracellular pathogens with nutrients. These CDC-mediated effects are well suited to the needs 
of extracellular pathogens. 
1.5.1 LLO  
L. monocytogenes is a facultative intracellular pathogen that, in humans, primarily causes 
self-resolving gastrointestinal infections. In immunocompromised individuals, L. monocytogenes 
can cause fatal systemic infections and, in pregnant women, placental infections that lead to 
pregnancy loss and systemic disease that results in death to the neonate (90). LLO is required for 
virulence in most if not all L. monocytogenes animal disease models, including acute systemic 
infection in mice, neonatal mice, pregnant mice and pregnant guinea pigs (65,91–96). The 
requirement for LLO in virulence can be recapitulated in tissue culture where it is required for L. 
monocytogenes to escape from a phagosomal membrane (97). Mutants lacking LLO are unable 
to escape from the phagosome and consequently unable to grow intracellularly. LLO-negative 
mutants are 5-logs less virulent in mice and cause immunosuppression via induction of the 
cytokine IL-10. Strikingly, replacement of LLO with other CDCs results in strains that can 
escape from a phagosome but then kill the infected host cell, thereby eliminating the intracellular 
replicative niche (2,98–100). 
The optimal pH for LLO activity is 5.5, while extracellular CDCs such as PFO and SLO 
have similar activities at pH 5.5 and pH 7, suggesting that LLO has adapted to the specific 
setting of the acidified phagosome (98,101). An early study into the molecular basis of this low 
optimal pH found that amino acid L461 was the main determinant, and that this leucine is not 
conserved in extracellular pathogens (102). Nonsynonymous mutations of L461 affect LLO 
activity and cytotoxicity. Mutants with a threonine substitution, the residue common in 
extracellular pathogen CDCs, were 100-fold less virulent in mice due to their increased 
cytotoxicity. The pH insensitivity of L461T may be caused by an increase in the rate of 
oligomerization. Later it was reported that LLO is denatured at neutral pH at temperatures 
greater than 30C, and that this was caused by charged amino acids within the transmembrane 
helices of domain 3 that act as a pH sensor (103). Thus, while LLO is maximally active in 
acidified phagosomes, in the host cell cytosol its activity is partially reduced and it has the 
potential to denature. This mechanism is not solely responsible for limiting the activity of LLO 
to the phagosome, but it does contribute to reducing LLO-mediated cytotoxicity and preserving 
the replicative niche. 
1.5.2 The LLO PEST-like Sequence 
The most distinctive and single largest contributing feature of LLO for the L. 
monocytogenes-specific lifestyle is a PEST-like sequence at the amino terminus of the protein 
(100,104). PEST-like sequences were originally described in eukaryotic proteins with short half-
lives and were thought to mediate those short half-lives, but it is now appreciated that they often 
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include another domain known as the polyproline type II (PPII) helix that mediates protein-
protein interactions (105–107). Structural and in vitro analyses have indicated that residues in 
PPII helix region play a role in oligomerization through intermolecular contacts (107). Deletion 
of 26 amino acids of LLO that include the PEST-like sequence has a minor effect on hemolytic 
activity; however, the bacteria are extremely cytotoxic in tissue culture and 10,000-fold less 
virulent in mice (100). 
Intracellular LLO exists in multiple forms, including 58kDa and 55kDa molecular weight 
species. The lighter species is absent during infection with the PEST-deletion mutant or mutants 
deficient in actin-based motility, suggesting the PEST-like sequence contributes to subcellular 
compartmentalization or processing of LLO (108). Additionally, independently of the PEST-like 
sequence, LLO is ubiquitylated and accumulates as a ladder of higher molecular weight species 
in the presence of proteasome inhibitors. LLO has an N-terminal lysine that serves as a 
destabilizing signal for the N-end rule pathway, which involves ubiquitylation and proteasomal 
degradation. Indeed, the short intracellular half-life of LLO was extended by replacing the N-
terminal lysine with stabilizing amino acids. However, the half-life extension only marginally 
affected cellular toxicity or virulence unless combined with mutations in the PEST-like sequence 
(109).  Future studies should aim to identify the precise site or sites of ubiquitylation and their 
roles in pathogenesis and cell biology. 
Consistent with the hypothesis that the LLO PEST-like sequence is important for 
intermolecular interactions, the PEST-like sequence contains three residues (S44, S48, and T51) 
that are predicted targets for MAPKs, and one or all of these residues are important for LLO 
phosphorylation inside of infected host cells (108). Studies on phosphorylation of the PEST-like 
sequence have been confounded by the observation that point mutations in the region result in 
increased protein production and attenuated virulence (108). For example, mutations that change 
the S44 codon to alanine, thereby preventing phosphorylation, have increased translation of 
LLO. However, mutations that change the S44 codon to other serine codons also have increased 
secretion and cytotoxicity—suggesting that the PEST-like sequence acts at the mRNA level to 
affect translation.  Further evidence of translational regulation is supported by the observation 
that mutations in the 5’ UTR alter protein expression (110,111). The unexplained effect of 
mutations in the PEST-like sequence on translation complicates the study of post-translational 
modifications in the PEST-like sequence.  
In addition to the above modifications, LLO is covalently modified by exogenously- and 
endogenously-produced S-glutathione at its cysteine residue (112). Modification of this residue 
may modulate the activity of all extracellular CDCs or restrict their activity to phagosomes 
containing oxidoreductases. For example, this cysteine has been implicated as a target for the 
phagosomal thiol-reductase known as GILT (113). GILT-/- mice and macrophages were more 
resistant to L. monocytogenes due to a defect in phagosomal escape, presumably because LLO 
activity was reduced by modification with glutathione or another low molecular weight thiol. 
Thus, the presence of a host oxidoreductase, such as GILT, can confer cellular specificity to 
CDC-producing pathogens by activating CDCs in the phagosome and promoting escape. 
However, mutant L. monocytogenes in which the LLO cysteine is substituted with an alanine 
have a very small virulence defect. 
Although a lot of work is still required to understand the role of LLO modifications inside 
host cells, recent work has provided a detailed mechanism describing how its N-terminus uses 
host cell machinery to promote LLO degradation (114). Within cells, LLO localized to puncta 
within the cytosol while LLO lacking the PEST-like sequence was found on the host plasma 
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membrane. This was due to interaction of the PEST-like sequence with the host Ap2a2 subunit 
of the clathrin-dependent endocytosis machinery, supporting a model in which LLO prevents 
cytotoxicity by accelerating the removal of LLO pores from the plasma membrane by 
endocytosis and targeting to autophagosomes. Interestingly, replacement of LLO PEST with the 
PEST-like sequence found on the human calcium receptor protein (HCaR), a G protein-coupled 
receptor that also interacts with Ap2a2, restored much of the virulence defect seen in a PEST 
deletion mutant. Though there are still some unanswered questions about the individual functions 
of this region of LLO, it is clear that the PEST-like sequence reduces the cytotoxicity of LLO. 
1.6 Contribution of LLO to L. monocytogenes Pathogenesis 
As discussed above, LLO has many other putative functions that are shared with CDCs 
produced by extracellular pathogens. Antibody to CDCs can often dramatically affect 
pathogenesis, as has been shown for PFO, PLY, ALO, and SLY (Bryant et al., 1993; Del Mar 
García-Suárez et al., 2004; Musher et al., 2001; Nakouzi et al., 2008; Takeuchi et al., 2014). In 
the case of L. monocytogenes, pretreatment of mice with 1 mg of LLO neutralizing antibody, 10-
times the amount of antibody required to effectively neutralize ALO and PLY in vivo, resulted in 
reduced bacterial burden (116). However, it was later shown that this amount of antibody 
blocked the activity of LLO inside of cells and prevented vacuolar escape (117,118). These 
results suggest that LLO is required for pathogenesis of L. monocytogenes because it enables 
vacuolar escape, and that extracellular LLO has little if any effect on pathogenesis. 
1.7 Future Considerations 
 Tissue culture models of infection provide a convenient way to study the effects that 
pathogens exert upon cells, and can shed insight into the host and bacterial factors required for 
any observed phenotypes. Bacterial mutants or antibody can be used to demonstrate the 
requirement for specific bacterial gene products in a given phenotype, and host mutants or 
specific inhibitors can be used to demonstrate host requirements. These are powerful strategies 
that have been used often to show the role of CDCs in the induction of host responses. For 
example, the conclusion that CDCs of S. pneumoniae, and L. monocytogenes induce 
inflammasome-dependent IL-1β secretion results from two distinct findings (1) deletion of the 
CDCs diminished IL-1β secretion and (2) deletion of inflammasome components also 
diminished IL-1β secretion from cells. However, once the host and bacterial requirements for an 
in vitro phenotype have been established, how do we accurately determine if and how the 
phenotype translates into an effect on pathogenesis in vivo?  
If a host is genetically tractable and the host factor in question is nonessential, it is possible 
to use a similar combinatorial approach, which can appropriately be called ‘genetics-squared’ 
(119). For some of the proposed LLO functions, genetic models can be used to verify the role of 
the host factors in pathogenesis. For example, Ubc9+/- mice have been used to demonstrate the 
importance of SUMOylation in control of Shigella flexneri, which is also a facultative 
intracellular pathogen, and could be used similarly for L. monocytogenes (47). Host gene 
deletions were used to understand the role of IL-1β in the pathogenesis of S. pneumoniae and L. 
monocytogenes. Caspase-1/11-/- mice infected with S. pneumoniae had increased bacterial 
burdens compared to WT mice, effectively demonstrating the role of caspase-1 in control of S. 
pneumoniae (68). However, PLY-deficient strains were not used in the in vivo experiments and 
thus we are left with questions: would the PLY-deficient strain grow better than wildtype S. 
pneumoniae in WT mice as a result of not activating the inflammasome, and if so, would that 
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benefit still occur in caspase-1-deficient mice? These approaches are not straightforward because 
of the multiple effects of individual virulence factors but nevertheless should be performed 
whenever possible. In L. monocytogenes, LLO showed the same capacity for activating caspase-
1 as other PFTs in vitro, while infection of caspase-1/11-/- mice yielded opposing results in vivo 
and, in our hands, had no effect on infection or immunity in mice (Sauer et al., 2011). Thus, 
similar tissue culture model results do not always translate directly to similar effects on 
pathogenesis. Furthermore, evaluating the role of LLO on caspase-1 activation—and most 
phenotypes for that matter—in vivo is difficult to assess because LLO-negative bacteria cannot 
grow intracellularly.  
How, then, can the role of LLO in vivo be validated separately from its essential role in 
vacuolar escape? One strategy that has been used to validate the significance of extracellular 
CDCs to pathogenesis is the use of neutralizing antibodies. Treatment of mice with PFO- PLY-, 
SLY- and ALO-neutralizing antibodies prior to infection with their respective pathogens resulted 
in a reduction in disease, thereby providing evidence for their role in disease. Many of the 
proposed functions of LLO, including MAPK activation, histone dephosphorylation, 
mitochondrial fragmentation, Ubc9 degradation, and caspase-1 activation occur upon addition of 
purified LLO to cells. It has been proposed that extracellular LLO that is secreted before 
bacterial invasion could cause the same effects in vivo. We propose the following experimental 
process to confirm or disprove that extracellular LLO causes these effects in vivo and that they 
have an effect on pathogenesis. First, these phenotypes must be identified following infection of 
mice; second, administration of an LLO-neutralizing antibody must reduce or abrogate the 
phenotypes; and third, the administration of LLO-neutralizing antibody must affect pathogenesis. 
Lastly, how can roles for cytosolic LLO be elucidated when deletion of the gene prevents 
phagosomal escape thereby preventing secretion of cytosolic LLO? Various approaches 
including inducible promoters have been used to show that LLO was necessary for cell-to-cell 
spread (5).  An alternative approach would be to incorporate an inducible degradation tag such as 
the auxin-inducible degron, where LLO could be targeted for degradation in the cytosol 
(120,121). However, this would be very difficult to adapt to animal experiments.  
The question remains, is LLO a phagosome-specific cytolysin or a multifunctional virulence 
factor? LLO has an abundance of features throughout its structure that allow it to mediate the 
escape of L. monocytogenes from a vacuole without causing excess cytotoxicity in the cytosol. 
Furthermore, it is absolutely required for disease because of its role in vacuolar escape. Thus, we 
believe that most evidence points to LLO being a phagosome-specific cytolysin. However, LLO 
may act extracellularly under some circumstances, perhaps in the intestine or during extracellular 
growth in the gall bladder (122). The notion that LLO can activate many of the same pathways as 
extracellular CDCs is intriguing, and the tools exist to validate whether or not LLO activates 
these pathways in the host in ways that affect the outcome of disease. 
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Chapter 2 
An inducible Cre-lox system to analyze the role of LLO in Listeria monocytogenes 
pathogenesis 
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2.1 Summary of Results 
Listeriolysin O (LLO) is the pore-forming cytolysin that allows Listeria monocytogenes to 
escape from phagocytic vacuoles and enter the host cell cytosol. LLO is expressed continuously 
during infection, but it has been a challenge to evaluate the importance of LLO secreted in the 
host cell cytosol because deletion of the gene encoding LLO (hly) prevents localization of L. 
monocytogenes to the cytosol. Here, we describe a L. monocytogenes strain (hlyfl) in which hly is 
flanked by loxP sites and Cre recombinase is under the transcriptional control of the L. 
monocytogenes actA promoter, which is highly induced in the host cell cytosol. In less than 2 
hours after infection of bone marrow-derived macrophages (BMMs), bacteria were 100% non-
hemolytic. hlyfl grew intracellularly to levels 10-fold greater than WT L. monocytogenes and was 
less cytotoxic. In an intravenous mouse model, 90% of bacteria were non-hemolytic within three 
hours in the spleen and eight hours in the liver. The loss of LLO led to a 2-log virulence defect in 
the spleen and a 4-log virulence defect in the liver compared to WT L. monocytogenes. Thus, the 
production of LLO in the cytosol has significant impact on the pathogenicity of L. 
monocytogenes. 
2.2 Introduction 
The field of microbial pathogenesis and the study of virulence factors has been guided for 
decades by Molecular Koch’s Postulates, which stipulate that inactivation of a gene encoding a 
suspected virulence factor should lead to measurable loss of virulence, and replacement of the 
gene should restore pathogenicity (123). Although targeted gene deletions are invaluable in 
determining the function of genes and pathways, there remain circumstances in which it is not 
possible to generate viable deletion mutants, or deletion of a gene encoding multiple functions 
precludes analysis of later functions.  The latter is the case for the gene encoding Listeriolysin O 
(hly) of Listeria monocytogenes. 
LLO belongs to a large family of cholesterol-dependent cytolysins (CDCs) which also 
includes: Perfringolysin of Clostridium perfringens, Streptolysin O of Streptococcus pyogenes, 
and Pneumolysin of Streptococcus pneumoniae (124). Importantly, LLO is the only CDC 
produced by an intracellular pathogen and its roles in pathogenesis are distinct and unique 
compared to related CDCs (125).  
Though the only clearly established role of LLO during infection is inside of L. 
monocytogenes-containing vacuoles, LLO is continuously secreted inside host cells. The 
continuous secretion of LLO has the potential to form pores in the host cell membrane and cause 
cell death. Mechanisms have been identified that suppress LLO activity within the host cytosol, 
lessening its potential toxicity, including: reduced activity at the neutral pH of the cytosol 
compared to the acidic pH of the vacuole, degradation by the proteasome, and translational 
repression by the 5’ coding sequence (25,102,108,110). Additionally, LLO co-opts host 
endocytosis machinery for removal of LLO from the plasma membrane (114). Mutations that 
abolish any of these control mechanisms increase L. monocytogenes cytotoxicity (126). 
However, these studies do not address potential activities of LLO secreted in the cytosol.  
Despite the numerous mechanisms that suppress LLO activity in the cytosol, it is still not 
clear whether LLO is suppressed to the point where it has no activity. Unfortunately, even the 
simplest questions have been difficult to address because of the early requirement for LLO, 
although strategies have been developed to examine this question. To show that LLO was 
required for escape from primary single-membrane and secondary double-membrane vacuoles, 
Gedde et al. noncovalently coupled purified LLO to hly L. monocytogenes and observed that 
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the bacteria were able to escape from the primary vacuole, but because of their inability to 
produce more LLO they became trapped in secondary vacuoles (4). Similarly, Dancz et al. 
demonstrated that L. monocytogenes expressing IPTG-inducible LLO remain trapped in vacuoles 
until addition of IPTG (5). Czuczman et al. studied L. monocytogenes in HeLa cells, in which 
LLO is not required for escape from the vacuole, and concluded that LLO causes localized 
plasma membrane damage that allows L. monocytogenes to hijack the cell efferocytosis 
machinery for cell-to-cell spread (127). Others have observed that LLO disrupts SUMOylation, 
modifies histones, and causes mitochondrial fragmentation during infection by simply adding 
purified LLO exogenously to cells (29,30,35,39,42). These studies have all tried to circumvent 
the requirement for LLO in the vacuole, but the diversity in the techniques used and their 
limitations makes it a challenge to integrate the conclusions into a complete picture. 
Additionally, these studies have not addressed the effects of these activities in mice.  
We have developed a tool for studying LLO that does not circumvent the requirement for 
LLO in vacuolar escape. We engineered a strain of L. monocytogenes that initially produces 
LLO, allowing it to escape from the vacuole. After escape from the vacuole hly is excised by 
Cre-lox-mediated DNA recombination and the strain becomes a hly mutant. Here we report 
rapid excision of hly in bone marrow-derived macrophages (BMMs) and in a mouse model. In 
BMMs, LLO secreted in the cytosol contributes to significant amounts of cytotoxicity. hlyfl grew 
to a level 10-fold higher than WT L. monocytogenes in BMMs, likely due to reduced cell death.  
2.3 Results 
2.3.1 Cre-lox allows for rapid excision of hly during infection of macrophages 
To study the role of LLO secreted in the cytosol during infection, we engineered a strain of 
L. monocytogenes, called hlyfl, to excise the gene encoding LLO, hly, following escape of L. 
monocytogenes from the phagocytic vacuole. Specifically, loxP sites were inserted into the L. 
monocytogenes chromosome to flank hly and an adjacent gene, tetL, which provides tetracycline 
resistance. Cre recombinase, which mediates DNA recombination between loxP sites, was 
inserted into the chromosome using the pPL2 integrative vector, and expressed under the control 
of the L. monocytogenes actA promoter, which is relatively inactive prior to vacuolar escape of 
L. monocytogenes and becomes highly expressed in the cytosol (Figure 1A). Thus, this strain is 
able to produce LLO initially to facilitate escape from the phagocytic vacuole but, once in the 
cytosol, hly is excised and LLO production ceases. To determine the efficiency of the system, 
BMMs were infected with hlyfl L. monocytogenes and bacteria from the infected cells were 
recovered at different time points and plated on blood-agar media. Secreted LLO causes rapid -
hemolysis and L. monocytogenes colonies that secrete LLO can be easily identified (Figure 1B). 
Prior to infection, hlyfl L. monocytogenes were grown in broth containing tetracycline to select 
against low-level excision of hly and tetL. By 30 minutes post-infection almost 90% of recovered 
CFU were non-hemolytic (Figure 1C). By 60 minutes post-infection, 98% of recovered CFU 
were non-hemolytic and by 90 minutes post-infection all colonies were non-hemolytic. 
Therefore, the excision of hly is rapid and complete during infection of BMMs.     
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Figure 2.1. hly is excised in the hlyfl strain in BMMs through DNA recombination.  
(A) Schematic of hlyfl L. monocytogenes strain. The hly and tetL (tetracycline resistance) 
genes are flanked by loxP sites. Cre recombinase is controlled by the actA promoter. 
Recombination between loxP sites leads to the excision of the DNA encoding hly and tetL; 
(B) Hemolytic and non-hemolytic colonies of hlyfl (C) To quantify the excision of hly, 
BMMs were infected with hlyfl and both hemolytic and non-hemolytic colonies were 
enumerated by plating bacteria on blood-agar media at different timepoints. Mean and SD 
of data pooled from three independent experiments are shown. (A and C) Reprinted from 
Cell Host & Microbe, Vol 23/Issue 6, Chen Chen, Brittney N. Nguyen, Gabriel Mitchell, 
Shally R. Margolis, Darren Ma, Daniel A. Portnoy, The Listeriolysin O PEST-like 
Sequence Co-opts AP-2-Mediated Endocytosis to Prevent Plasma Membrane Damage 
during Listeria Infection, 786-795., Copyright (2018), with permission from Elsevier. 
 
 
  
16 
 
2.3.2 LLO secreted in the cytosol affects intracellular growth and contributes to 
cytotoxicity 
To determine whether secretion of LLO by L. monocytogenes in the cytosol affects the 
growth of the bacteria in cells, intracellular growth was evaluated in BMMs. During the first five 
hours of infection, hlyfl L. monocytogenes grew identically to WT L. monocytogenes and ΔactA, 
which is defective in actin-based motility and therefore defective in cell-to-cell spread (Fig 2A). 
However, after five hours of infection the growth of the strains diverged. Between five and 
twenty-four hours of infection, the number of WT L. monocytogenes plateaued and then 
declined, but the number of recovered hlyfl L. monocytogenes increased to 10-fold more than the 
maximum of WT and remained elevated, suggesting that secretion of LLO in the cytosol 
negatively impacts growth of WT.  
 WT L. monocytogenes has the ability to spread to and replicate in neighboring cells. If 
hlyfl has a defect in escape from secondary vacuoles that would limit its ability to replicate in 
neighboring cells, the difference in growth between WT and hlyfl may reflect both the effects of 
LLO secreted in the cytosol and growth following cell-to-cell spread. To analyze the effects of 
LLO in the cytosol without complication by cell-to-cell spread, we compared growth of hlyfl in a 
ΔactA background (ΔactA hlyfl) to ΔactA, which is defective in actin-based motility and 
therefore defective in cell-to-cell spread. During the first eight hours of infection, ΔactA and 
ΔactA hlyfl grew similarly to WT. However, between eight and twenty-four hours, the number of 
ΔactA bacteria decreased dramatically, whereas ΔactA hlyfl decreased much less – having as 
much as 100-fold more bacteria than ΔactA. The rapid loss of ΔactA CFU, which is due to the 
influx of gentamicin (128), was partially rescued by deletion of hly in the cytosol, indicating that 
the decline of ΔactA in cells is largely LLO-dependent. 
The ability of LLO to form pores in cholesterol-containing cell membranes is well 
documented. We hypothesized that the growth of WT L. monocytogenes could be restricted by 
LLO-induced cytotoxicity because LLO has the potential to bind to the cell membrane and cause 
cell death. To quantify the amount of cell death caused by L. monocytogenes infection, 
cytotoxicity was measured by LDH release assay (Fig 2B). After a 24-hour infection of BMMs, 
43% of cells were killed by WT L. monocytogenes infection. Only 22% of cells were killed by 
hlyfl L. monocytogenes infection, indicating that LLO secreted in the cytosol contributes 
significantly to cytotoxicity during infection.  
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Figure 2.2. hlyfl grew intracellularly and had reduced cytotoxicity but had a defect in cell-
to-cell spread.  
(A) BMMs were infected at an MOI of 0.17 with L. monocytogenes and intracellular CFU 
were enumerated at different times. Three biological replicates were measured in each 
experiment, and experimental results were combined. For ΔactA and ΔactA hlyfl n=6. For WT 
and hlyfl n=9. Mean and SEM are shown. Results were log-transformed and means were 
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compared using Holm Sidak’s multiple comparisons test. (B) BMMs were infected with L. 
monocytogenes at a MOI of 4 for 24 hours. LDH release was measured and values were 
normalized according to lysis with 1% Triton-X 100 representing 100% LDH release and 
the condition with the smallest mean value representing 0% LDH release. The average of 
three technical replicates per experiment, from three independent experiments are 
presented. Means were compared using an unpaired t-test. (C) BMMs were infected with 
L. monocytogenes and cell-to-cell spread was quantified 5 hours post infection. WT n=67, 
hlyfl n=60. Means were compared using an unpaired t-test. (D) L2 cells were infected with 
L. monocytogenes at a MOI of 0.1. Plaque size was measured after 3 days and values were 
normalized to WT plaque size. Mean and SEM for data pooled from three independent 
experiments is shown. WT n=19, Δhly + hlyfl n=14. N.D. indicates no plaques were 
detectable. (E) Representative images of the BMMs infected with L. monocytogenes for 
cell-to-cell spread analysis in (C). Dashed lines are used to indicate the initially-infected 
cells.  
2.3.3 Cell death caused by LLO is not apoptosis or necroptosis 
When the impacts of cell-to-cell spread on growth in BMMs were removed by comparing 
actA to actA hlyfl, deletion of hly in the cytosol still provided a growth advantage. The results 
indicate that WT L. monocytogenes has a growth defect due to LLO-dependent cytotoxicity. To 
determine the type of cytotoxicity caused by LLO, BMMs were infected with WT and hlyfl L. 
monocytogenes and treated with the pan-caspase inhibitor zVAD-fmk, which blocks apoptotic 
cell death, or Necrostatin-1, which blocks necroptosis (Fig 2.3A). Treatment of infected BMMs 
with zVAD-fmk or Necrostatin-1 did not reduce LDH release caused by WT L. monocytogenes 
infection. Surprisingly, zVAD-fmk treatment of macrophages infected with WT or hlyfl L. 
monocytogenes resulted in significantly increased cell death and reduced growth in BMMs 
(Fig2.3A-B). To determine the type of cell death caused by infection in combination with zVAD-
fmk treatment, zVAD-fmk was used in combination with Necrostatin-1. Necrostatin-1 treatment 
significantly reduced zVAD-fmk-dependent cytotoxicity (Fig 2.3A), suggesting that zVAD-fmk 
treatment leads to necroptosis of L. monocytogenes-infected BMMs. To confirm that zVAD-fmk 
leads to necroptosis, Caspase-1/11-/- and Rip3k-/- BMMs were infected in the presence and 
absence of zVAD-fmk. Cytotoxicity was significantly increased by zVAD-fmk in Caspase-1/11-/- 
BMMs (Fig 2.3C), indicating that zVAD-fmk did not lead to pyroptotic cell death. Additionally, 
WT L. monocytogenes infection resulted in significantly higher LDH release than hlyfl L. 
monocytogenes in Caspase-1/11-/- BMMs, similar to WT BMMs. However, zVAD-fmk treatment 
did not result in increased cell death in Ripk3-/- BMMs (Fig 2.3D). Together, our results suggest 
that LLO-mediated cytotoxicity is not apoptosis, necroptosis, or pyroptosis, and that zVAD-fmk 
treatment in combination with L. monocytogenes infection leads to necroptosis.  
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Figure 2.3. Inhibition of caspases results in increased cell death during infection.  
WT BMMs (A), Caspase-1/11-/- BMMs (C) or Ripk3-/- BMMs (D) were infected with L. 
monocytogenes at a MOI of 4 for 24 hours. (B) BMMs were infected at an MOI of 0.17 
with L. monocytogenes and intracellular CFU were enumerated at different times. Data are 
pooled from two independent experiments. For cell death inhibitors, cells were pretreated 
for 1 hour with 10 µM zVAD-fmk (zVAD) and/or 50 µM Necrostatin-1 (nec). LDH 
release was measured and values were normalized according to lysis with 1% Triton-X 100 
representing 100% LDH release and the uninfected representing 0% LDH release. Mean 
and SEM for data pooled from 2-3 independent experiments is shown. Data were analyzed 
using a Holm-Sidak Multiple Comparisons test. 
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2.3.4 hly is excised in vivo and its excision reduces virulence 
To quantify the efficiency of the hlyfl Cre-lox system in vivo, C57BL/6J mice were infected 
intravenously with 105 CFU of hlyfl L. monocytogenes (Fig 2.4). Hemolytic capacity of the 
inoculum was verified by plating on blood agar. At 1, 2, 3, 5, 8, and 24 hours post-infection, 
bacteria were recovered from the spleen and liver and plated on blood agar and both hemolytic 
and non-hemolytic CFU were enumerated. In the spleen (Fig 2.4A), less than 20% of bacteria 
were hemolytic one hour post-infection. Hemolytic bacteria represented less than 2% of the 
population three hours post-infection and were nearly undetectable five hours post-infection. 24 
hours post infection, a small population of hemolytic bacteria were detected in the spleen (see 
discussion). In the liver (Fig 2.4B), excision of hly was slower than in the spleen. One hour post-
infection, only 35% of bacteria were non-hemolytic; eight hours post-infection 95% of bacteria 
were non-hemolytic and hemolytic colonies were undetectable by 24 hours post-infection.  
 
Figure 2.4. hlyfl recombines in vivo and is attenuated in mice.  
(A and B) C57BL/6J mice were infected with 1 x 105 CFU of hlyfl L. monocytogenes. For 
each timepoint, hemolytic and non-hemolytic colonies recovered from the (A) spleen and 
(B) liver were enumerated. % Total Hemolytic colonies were calculated for each mouse. 
Mean and SEM are shown. Data are pooled from two independent experiments. For each 
timepoint, n=6. (C and D) CD-1 mice were infected with 1 x 105 CFU of L. 
monocytogenes. 48 hours post-infection, CFU from the (C) spleen and (D) liver were 
enumerated. Data are pooled from three independent experiments and medians are shown. 
n=13. Means were compared using Holm Sidak’s multiple comparisons test. 
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To determine the importance of LLO after escape of L. monocytogenes from the initial 
vacuole, we characterized hlyfl L. monocytogenes using a mouse model of virulence. CD-1 mice 
were infected intravenously with 105 CFU of L. monocytogenes (Fig 2.4). WT L. monocytogenes 
grew to 107 CFU in both the spleen and liver, while hly L. monocytogenes was extremely 
attenuated with bacteria from the spleen and liver near or below the limit of detection in most 
mice. Interestingly, hlyfl L. monocytogenes had a moderate level of attenuation. 104 CFU were 
recovered from the spleen, representing a statistically-significant 3-log reduction in virulence 
compared to WT, although a smaller reduction in virulence than that of hly (Fig 2.4C). In the 
liver, less than 103 CFU were recovered, similar to hly (Fig 2.4D).  
2.3.5 Vaccination with hlyfl confers protective immunity 
The two requirements for a vaccine are safety and efficacy. In Figure 3, we showed that hlyfl 
is highly attenuated, and thus satisfies the safety requirement. To test the efficacy of hlyfl L. 
monocytogenes as a vaccine, protection of hlyfl was compared to protection conferred by actA, 
which is well-established as an attenuated and effective vaccine strain (129), and hly, which 
does not confer strong protection. C57BL/6J mice were vaccinated with either 103 or 105 hlyfl, 
103 or 105 actA, or 108 hly. Four weeks post-vaccination, the mice were challenged with a 
lethal dose of WT L. monocytogenes. Three days post-challenge, CFU from the spleen were 
enumerated (Fig 2.5A). Vaccination with 105 CFU of hlyfl provided 5-logs of protection, albeit 
less protection than actA, while vaccination with 105 CFU of hly did not confer protection. 
However, vaccination with 103 hlyfl was not as protective as 103 actA.  
 
Figure 2.5. Vaccination with hlyfl confers protective immunity in mice.  
(A) C57BL/6J mice were vaccinated with 103 or 105 CFU of L. monocytogenes. 4 weeks 
post-vaccination, mice were challenged with 5 x 104 – 1 x 105 CFU of WT L. 
monocytogenes. Three days post-challenge, CFU were enumerated. Data are pooled from 
2-3 independent experiments. (B) C57BL/6J mice were vaccinated with 103 ΔactA or hlyfl 
L. monocytogenes or 108 Δhly L. monocytogenes +/- treatment with αIL-10R antibody. 
Mice were challenged with 5 x 104 CFU of WT L. monocytogenes. Three days post-
challenge, CFU were enumerated. Data are pooled from 2 independent experiments. Data 
were analyzed using a Holm-Sidak Multiple Comparisons test. X indicates a mouse that 
died from the WT challenge.  
22 
 
As vaccination with vacuole-confined hly is inhibited by the secretion of the 
immunosuppressive cytokine IL-10 (130), we hypothesized that hlyfl is also inhibited by IL-10 
because it is defective in cell-to-cell spread and remains confined in secondary vacuoles. To test 
this hypothesis, we performed protection studies using an IL-10 receptor blocking antibody (αIL-
10R), which improves the protective capacity of hly (130). Indeed, administration of αIL-10R 
improved the protective capacity of hly and hlyfl but not actA L. monocytogenes (Fig 2.5B). 
Furthermore, the protection conferred by hlyfl was improved to levels similar to those conferred 
by vaccination with actA. Thus, hlyfl is a highly attenuated strain of L. monocytogenes capable 
of inducing protective immunity, though its protection is reduced compared to actA likely due 
to IL-10.  
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Figure 2.6. Intracellular lifecycles of WT and hlyfl L. monocytogenes.  
WT L. monocytogenes enters cells and secretes LLO, allowing it to escape phagocytic 
vacuoles and enter the cytosol. In the cytosol, the bacteria replicate to high numbers and 
continuously secrete LLO. L. monocytogenes uses actin-based motility to form membrane 
protrusions, which are engulfed by neighboring cells and resolved into double-membraned 
vacuoles. LLO facilitates bacterial escape from secondary vacuoles and the cycle 
continues. hlyfl L. monocytogenes enters cells and secretes LLO, allowing bacterial entry 
into the cytosol. In the cytosol, Cre-recombinase expression is upregulated and hly is 
deleted. Bacteria in the cytosol replicate to high numbers but do not produce LLO. hlyfl L. 
monocytogenes spreads to neighboring cells but remains trapped in secondary vacuoles.  
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2.4 Discussion 
As a member of the cholesterol-dependent cytolysin (CDC) family of pore-forming toxins, 
LLO is unique as the only CDC that is secreted by an intracellular pathogen and therefore the 
only CDC that primarily acts on cells from within. Therefore, LLO likely affects cells in ways 
that extracellular CDCs do not. Yet, because deletion of hly prevents study of the effects of LLO 
in the cytosol, other studies have utilized the application of exogenous purified LLO to study its 
effects (29,30,35,39,42). Here we described a L. monocytogenes strain that uses a Cre-lox 
system to delete hly following vacuolar escape. This strain, hlyfl, became 100% non-hemolytic 
less than 1.5 hours after infection of macrophages (Fig 1C) and replicated to high numbers in the 
cytosol (Fig 2A and 2E). hly excision after vacuolar escape allows the study of LLO functions in 
the cytosol separate from its role in vacuolar escape.  
2.4.1 Insights into the effects of LLO during infection 
LLO is a pore-forming toxin that oligomerizes and forms pores in cholesterol-containing 
membranes, including the host cell vacuolar and plasma membranes (9,10). Secretion of LLO in 
the cytosol has the potential to damage the host cell plasma membrane. Although multiple 
mechanisms limit LLO damage to the cell plasma membrane, it has been difficult to establish 
whether these mechanisms are entirely effective in preventing cell death (125). Here we showed 
that L. monocytogenes that does not produce LLO in the cytosol replicates to greater numbers in 
macrophages and is less cytotoxic. The revelation that LLO secreted in the cytosol is cytotoxic 
makes it more curious that L. monocytogenes continuously secretes LLO. It is possible that the 
continuous production of LLO is to ensure a rapid escape from secondary vacuoles, as defects 
that reduce cell-to-cell spread are highly attenuated.  
It is also possible that the innate immune response to LLO-induced cell death contributes to 
pathogenesis. In the host cell cytosol, infrequent lysis of L. monocytogenes induces pyroptotic 
cell death via the AIM2 inflammasome (131). Some forms of cell death are thought to inhibit the 
generation of protective immunity. Strains of L. monocytogenes engineered to induce pyroptosis, 
necrosis or apoptosis inhibit the generation of protective immunity (132). Thus, it is likely that 
LLO-induced cell death also affects the immune response to L. monocytogenes infection. Our 
results indicated that LLO does not lead to apoptosis, necroptosis, or pyroptosis. Therefore, cell 
death caused by LLO may be a different type of programmed cell death or, more likely, 
unprogrammed necrosis.  
Strikingly, we observed that inhibition of caspases with the pan-caspase inhibitor zVAD-
fmk resulted in necroptotic cell death during L. monocytogenes infection. The apoptosis and 
necroptosis cell death pathways are tightly connected, such that induction of apoptosis prevents 
necroptosis (133). Many of the signals that induce apoptosis can also induce necroptosis, such as 
activation of TNF receptors. As a result, caspase inhibition with zVAD-fmk in cells stimulated 
with TNF, for example, can lead to necroptosis (133). In mice, L. monocytogenes causes rapid 
necroptosis of Kupffer cells in the liver, which promotes clearance of the infection (134). It has 
been suggested that necroptosis is a host immune strategy that is protective against L. 
monocytogenes infection (135). Our results suggest that, in BMMs, L. monocytogenes infection 
activates caspases that prevent necroptotic cell death. However, L. monocytogenes-infected 
BMMs do not die by apoptosis (136). Therefore, it is possible that L. monocytogenes has a 
mechanism for activating apoptotic caspases to prevent necroptosis, while also inhibiting the 
complete execution of the apoptotic cell death pathway, as an intracellular survival strategy. 
How L. monocytogenes promotes cell survival merits further investigation.  
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Analysis of the kinetics of hly deletion, specifically the more rapid deletion in the spleen 
compared to the liver, revealed differences in the environments experienced by L. 
monocytogenes. CD169+ macrophages that are localized to the marginal zone of the spleen and 
dendritic cells are thought to be the first splenic cell types infected by L. monocytogenes upon 
intravenous inoculation (137,138). Three hours post infection, the majority of L. monocytogenes 
in the spleen are trapped within CD169+ macrophages (137). Following infection with hlyfl, 
bacteria in the spleen became non-hemolytic at a rate similar to in BMMs, with almost complete 
loss of hemolytic capacity three hours post-infection, suggesting that infection of BMMs closely 
models infection in the spleen with respect to activation of virulence genes. However, bacteria 
became non-hemolytic at a much slower rate in the liver, with greater than 20% of bacteria 
remaining hemolytic at 5 hours post-infection and complete loss of hemolysis between eight and 
24 hours post-infection. In the liver, four hours after infection with L. monocytogenes 100% of 
infected cells are tissue-resident macrophages, known as Kupffer cells (134). Bacteria that are 
not killed by the Kupffer cells can transfer to hepatocytes, which become heavily infected (139). 
Over the next couple days, infected Kupffer cells die by necroptosis; infiltrating neutrophils and 
monocyte-derived macrophages lyse infected hepatocytes and become the primarily infected 
cells (139–141). It is possible that hlyfl became non-hemolytic slowly in the liver because actA 
expression was not efficiently upregulated in Kupffer cells, and Cre-lox recombination only 
occurred after the bacteria were transferred to hepatocytes, neutrophils and/or monocyte-derived 
macrophages. If this is the case, it would be interesting to understand why the intracellular 
environment of a Kupffer cell does not activate actA expression like other cells. Alternatively, 
the bacteria that became non-hemolytic during the first 8 hours of infection could represent the 
population of bacteria inside Kupffer cells, hepatocytes and/or infiltrating neutrophils and 
monocyte-derived macrophages, and the bacteria that remained hemolytic may represent an 
extracellular population of bacteria in the liver. A small population of extracellular bacteria 
associated with nonparenchymal cells in the liver six hours after infection has been previously 
identified, though it is not clear whether these bacteria became extracellular following lysis of 
infected hepatocytes, or whether they never infected cells (142).  
2.4.2 Limitations of hlyfl 
Although we have successfully employed hlyfl to demonstrate the contribution of LLO to 
cytotoxicity in macrophages, this system is limited by the fact that loss of LLO is permanent and 
not conditional to the environment of the cytosol. As a result, hlyfl became trapped in secondary 
vacuoles and was defective in cell-to-cell spread (Fig 2C-E). Bacteria that are released from the 
cytosol upon cell lysis also behave like LLO-minus mutants. The inability to escape subsequent 
vacuoles likely explains the attenuation of hlyfl in mice (Fig 3C and 3D), and why hlyfl 
vaccination was improved by αIL-10R antibody (Fig 4B).  
An additional complication of hlyfl is that Cre-lox recombination is susceptible to 
inactivation. A previous study in which a transposon library was generated in a strain of L. 
monocytogenes with Cre-lox identified transposon insertions in the actA promoter driving cre 
expression and loxP sites that prevented recombination. We observed a population of hemolytic 
bacteria in the spleen that expanded between eight- and 24 hours post-infection. We isolated 
several colonies of hemolytic bacteria 24 hours post-infection and reinfected BMMs, and 
bacteria were 100% hemolytic five hours post-infection (data not shown). It is possible that these 
hemolytic bacteria are the progeny of a founding bacterium that had a mutation in its Cre-lox 
machinery that prevented recombination from occurring.     
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In the future, the ideal tool to study the cytosolic effects of LLO in mice would not secrete 
LLO in the host cell cytosol but could secrete LLO upon entry into secondary cells to continue 
the life cycle. Nevertheless, we believe hlyfl is well-suited for studying LLO secreted in the 
cytosol in cells, and insights gained from study of hlyfl in cells can be translated to the whole 
animal setting using various mouse models. 
2.5 Conclusion 
Cre-lox recombination has been a popular tool for the study of plants and mice for many 
decades (143–145). In bacteria its use has been more limited, and it has only been used a few 
times in L. monocytogenes. Previously in L. monocytogenes, Cre-lox was used to generate a 
strain that cannot replicate following activation of the actA promoter by flanking essential genes 
near the origin of replication with loxP sites and driving Cre expression with the actA promoter 
(146). This strain is highly attenuated and potently activates the CD8+ T-cell response and thus 
is a candidate vaccine-delivery system (147). In another instance, a strain of L. monocytogenes 
that deletes actA in the host cell cytosol was used to show that ActA expressed in the host cell 
cytosol contributes to cell-to-cell spread and simultaneously allows L. monocytogenes to avoid 
xenophagy (148). This works represents the first use of Cre-lox recombination to study the 
function of a virulence factor that is active at temporally and spatially distinct periods. We 
believe that this system has the promise to uncover many effects of LLO secreted in the cytosol 
and could also uniquely contribute to better understanding the cellular responses to membrane 
damage from an intracellularly secreted pore-forming toxin.  
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2.6 Materials and Methods  
Construction of hlyfl 
hlyfl was constructed by integrating two plasmids, one encoding hly and tetL flanked by loxP 
sites and the other encoding cre downstream of the actA promoter, into a hly strain of L. 
monocytogenes. The hly and tetL genes were cloned into pPL1 and flanked by lox66/lox71 loxP 
sites such that Cre expression resulted in excision of the region flanked by loxP sites (fl). The 
resulting plasmid (pPL1-hlyfl) was transformed into SM10 E. Coli. The cre recombinase gene 
was previously engineered downstream of the actA promoter in pPL2e, yielding the plasmid 
pPL2e-actA-cre, which was also transformed into SM10 E. Coli. Transconjugation was 
performed to integrate both plasmids into hly L. monocytogenes in a stepwise manner. First, 
pPL1-hlyfl was transconjugated with hly L. monocytogenes and transconjugate colonies that 
were resistant to streptomycin (200g/mL) and chloramphenicol (7.5 g/mL) were selected. 
Second, hly pPL1-hlyfl was transconjugated with pPL2e-actA-cre, and transconjugate colonies 
resistant to streptomycin, chloramphenicol, and erythroymycin (1 g/mL) were selected. 
Similarly, actA hlyfl was engineered by transconjugating pPL1-hlyfl and pPL2e-actA-cre into 
actAhly. The hlyfl complement strain was engineered by transconjugating hly with pPL1-
hlyfl.  
A control pPL1 plasmid (pPL1-tetLfl) encoding tetL, but not hly, flanked by loxP sites was 
engineered by excising hly from pPL1-hlyfl.  The hly control strain was engineered by 
transconjugating hly with pPL1-tetL. The WT control strain was engineered by 
transconjugating WT with pPL1-tetLfl. The actA control strain was engineered by 
transconjugating actA with pPL1-tetLfl. 
 
Bacterial Culture 
Bacteria were grown overnight at 37C in BHI containing 200g/mL streptomycin, and 
bacteria with tetL were additionally grown in 2 g/mL tetracycline. Overnight cultures were 
diluted 1:200 and grown in BHI containing streptomycin (for bacteria without tetL) or 
streptomycin and tetracycline (for bacteria with tetL) at 37C, shaking, to an optical density of 
0.5. These cultures were then pelleted by centrifugation, and resuspended in phosphate-buffered 
solution (PBS) containing 9% glycerol. These cultures were then aliquoted and frozen at -80C. 
Aliquots were thawed and used directly for experiments.  
 
Preparation of M-CSF 
3T3 cell media was prepared using DMEM with 10% FBS, 1% L-Glutamine, and 1% 
Sodium pyruvate, with or without 1x Penicillin Streptomycin Solution (“Pen/Strep”; Corning). 
107 M-CSF-producing 3T3 cells were seeded into a T75 flask with 20mL media containing 
Pen/Strep and grown at 37°C 5% CO2 (Day 1). To split cells, media was aspirated, cells were 
washed with warm PBS, and incubated with 0.05% Trypsin-EDTA (Gibco) for five minutes at 
37°C. On day 4, cells were split to a T225 in 50mL media containing Pen/Strep. On day 7, cells 
were split to five T225 flasks in media without Pen/Strep. On day 9 or 10, when cells when cells 
were 100% confluent, the five T225 flasks were split into 25 T225 flasks and grown until 100% 
confluent (about 3 days) and an additional two days (about 5 days total) in media without 
Pen/Strep. On day 14 or 15, supernatant was removed from all flasks, filter sterilized with a 
0.2µM bottle filter, and stored at 4°C. 50mL fresh media without Pen/Strep was added back to 
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each T225 and flasks were incubated an additional 3 days. On day 17 or 18, supernatants were 
collected as before, and combined with the previous supernatants. Supernatants were stored at -
20°C and used as the source of M-CSF for bone marrow-derived macrophage preparation and 
culture. 
 
Bone Marrow-Derived Macrophage Culture 
BMM growth media was prepared using high glucose DMEM (Thermo Fisher Scientific) 
with 20% Fetal Bovine Serum (Seradigm), 1% L-glutamine (Corning), 1% Sodium pyruvate 
(Corning), 14mM 2-Mercaptoethanol (Gibco), and 10% 3T3 cell supernatant (from M-CSF-
producing 3T3 cells). Macrophages were prepared from the femurs of C57BL/6J mice. Ripk3-/- 
femurs were generously provided by Anita Sil. Femurs were isolated, sterilized with 70% 
ethanol, and crushed with a mortar and pestle in BMM growth media. Cells were strained 
through a 70µM filter and distributed into ten 150-mm non-TC dishes in 30mL BMM culture 
medium. An additional 30mL BMM culture medium was added at day 3. After cells were 
incubated for a total of seven days at 37C with 5% C02, cells were harvested and frozen at -
80C in BMM culture medium with 10% Fetal Bovine Serum and 10% DMSO (Sigma) added.   
 
Blood Agar Media 
Blood agar media was prepared using the following recipe for 1L of media: 5g yeast extract, 
10g tryptone (BTS), 10g NaCl (Fisher), 10.48g MOPS (Sigma), 1g activated charcoal, 5g 
SuperPure Agar (BTS), 957.5mL MilliQ water (Millipore), and 10N NaOH to bring pH to 7.3. 
Media was autoclaved and cooled prior to addition of 12.5mL 304g/L glucose-1-phosphate 
(Sigma) and 25mL defibrinated Sheep’s blood (Hemostat).  
 
Hemolysis in BMMs 
A 60mm non-TC dish with 15 12mm glass coverslips was seeded with 3 x 106 BMMs. The 
following day, the cells were infected with 2 x 105 CFU hlyfl for 30 minutes. Then, cells were 
washed with PBS and BMM media with 50µg/mL gentamicin was added. At each timepoint, 
coverslips were removed from the dish and placed in water to lyse the cells. Bacteria were plated 
on blood-agar media. Plates were incubated overnight at 37C and then transferred to 4C until 
halos surrounding hemolytic colonies were clear. Hemolytic and ahemolytic colonies were 
enumerated. 
 
Hemolysis in Mice 
C57BL/6J (Jackson Labs) mice were infected with 1 x 105 CFU of hlyfl L. monocytogenes. 
At 0, 1, 2, 3, 5, 8, and 24 hours post infection mice were euthanized (3 mice per timepoint) and 
spleens and livers were harvested, homogenized, and plated on blood-agar media. Plates were 
incubated overnight at 37C and then transferred to 4C until halos surrounding hemolytic 
colonies were clear. Hemolytic and ahemolytic colonies were enumerated. 
 
Lactate Dehydrogenase (LDH) Assay 
BMMs were seeded into a 24-well plate with 5 x 105 BMMs/well. The following day, cells 
were infected with 2x106 CFU L. monocytogenes for 30 minutes. Then, cells were washed with 
PBS and BMM media containing 5% FBS and 50μg/mL gentamicin was added to wells. 24 
hours post-infection LDH Assay was performed as previously described (131). 
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Intracellular growth curves 
3 × 106 BMMs were plated in 60 mm non-TC-treated Petri dishes with 15 12mm glass 
coverslips in each dish. The following day, two dishes per strain were infected with 5 x 105 CFU 
(MOI=0.17) and intracellular growth curves were performed as described previously (96). 
 
Plaque assay 
Six-well plates were seeded with 1.2 x 106 L2 cells per well. The plaque assay was 
performed as previously described (149). 
 
Cell Spreading Assay 
BMMs were seeded into a 24-well plate with glass coverslips in each well, at 3.5 x 105 
cells/well. Wells were infected with bacteria. 30 minutes post infection, cells were washed with 
PBS and BMM media containing 50μg/mL gentamicin was added. At five hours post-infection, 
coverslips were removed and cells were fixed with 100% methanol and stained using Diff-Quik 
stain. Coverslips were mounted onto glass slides using Permount (Fisher Chemical). Light 
microscopy was performed using a BZ-X700 microscope (KEYENCE) and a 60x objective lens. 
Cell spread index was calculated by counting the number of cells in an infectious focus 
containing 5 or more bacteria and subtracting one cell so that the cell spread index represents the 
number of cells that were spread to from the initially infected cell. Analysis was performed 
blindly. In total, 60 hlyfl and 67 WT infectious foci were analyzed. 
 
Animal Use Ethics Statement 
All animal work was done in strict accordance with university regulations. Protocols were 
reviewed and approved by the Animal Care and Use Committee at the University of California, 
Berkeley AUP-2016-05-8811. 
 
Virulence in Mice 
Eight-week-old female CD-1 mice (Charles River) were infected intravenously with 1 × 
105 CFU in 200µL PBS. Forty-eight hours post-infection the mice were euthanized and spleens 
and livers were harvested, homogenized in 0.1% IGEPAL CA-630 (Sigma) in water, and plated 
on LB Agar with 200µg/mL streptomycin for enumeration of bacterial burdens.  
 
Vaccination of Mice  
Eight-to-ten-week-old female C57BL/6J mice (Jackson Laboratories) were vaccinated by 
intravenous injection of L. monocytogenes in 200µL PBS. Four-weeks post vaccination, mice 
were challenged with 5 x 104 CFU WT L. monocytogenes injected intravenously in 200µL PBS. 
Three-days post challenge, mice were euthanized, and spleens and livers were harvested, 
homogenized in 0.1% IGEPAL CA-630 (Sigma), and plated on LB Agar with 200µg/mL 
streptomycin for enumeration of bacterial burdens. Mice treated with αIL-10R antibody (Clone 
1B1.3A, Bio X Cell) were injected with 250µg of antibody in 100µL PBS two hours prior to 
vaccination.  
 
Statistical Analysis 
Data were analyzed using GraphPad Prism 8. For mouse CFU experiments, data was log-
transformed prior to performing statistical analysis. * indicates P <0.05; ** indicates P <0.01, 
*** indicates P <0.001, **** indicates P <0.0001; ns indicates no statistical significance.  
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Table 2. Strains  
Strain Name Strain Background 
Plasmid 
1 
Plasmid 
2 
Strain 
Number 
Reference 
hlyfl hly 
pPL1-hlyfl pPL2e-
actA-cre 
DP-L6648 (114) 
hly + hlyfl 
(complement) 
hly pPL1-hlyfl - 
 
DP-L6647 (114) 
WT 
WT 10403S 
(DP-L6234; DP-L4056 
phage-cured) 
pPL1-tetLfl - DP-L6896 This study 
hly 
hly 
(DP-L6236; DP-L4027 
phage-cured) 
pPL1-tetLfl - DP-L6897 This study 
actA 
actA 
(DP-L6235; DP-L4029 
phage-cured) 
pPL1-tetLfl - DP-L6894 This study 
actA hlyfl 
actAhly phage-cured 
(DP-L6237) 
pPL1-hlyfl pPL2e-
actA-cre 
DP-L6883 This study 
pPL1-hlyfl 
SM10   DP-E6869 This study 
pPL1-tetLfl 
SM10   DP-E6892 This study 
pPL2e-actA-
cre 
SM10   DP-E6233 (146) 
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Chapter 3  
Characterization of TLR2 and endosomal TLR-mediated secretion of IL-10 and immune 
suppression in response to phagosome-confined Listeria monocytogenes 
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3.1 Summary of Results 
Listeria monocytogenes is a facultative intracellular pathogen that induces a robust adaptive 
immune response in mice characterized by the induction of antigen specific CD8+ T-cells. 
However, L. monocytogenes mutants unable to escape phagosomes fail to induce a robust 
adaptive immune response and suppress the response to wildtype bacteria when co-
administered.  The capacity to suppress immunity can be reversed by blocking IL-10.  In this 
study, we sought to understand the host cell signaling pathways that lead to secretion of IL-10 in 
response to phagosome-confined L. monocytogenes (Δhly). We conducted a transposon screen to 
identify Δhly L. monocytogenes mutants that induced significantly more or less IL-10 secretion 
in bone marrow-derived macrophages (BMMs). A transposon insertion in lgt, which encodes 
phosphatidylglycerol-prolipoprotein diacylglyceryl transferase and is essential for the formation 
of lipoproteins, significantly reduced IL-10 secretion from BMMs. Mutants with transposon 
insertions in pgdA and oatA, which encode peptidoglycan N-acetylglucosamine deacetylase and 
O-acetyltransferase and are sensitive to lysozyme, induced enhanced IL-10 secretion. In BMMs, 
secretion of IL-10 in response to infection with the parental strain was mostly TLR2-dependent, 
while IL-10 induced by strains engineered to lyse was dependent on TLR2 and Unc93b1.  In 
mice, nucleic acid-sensing TLRs primarily mediated the IL-10 response to vacuole-confined L. 
monocytogenes. Co-administration of Δhly and ΔactA resulted in suppressed immunity in WT 
mice, but not in mice with mutations in Unc93b1. These data revealed that secretion of IL-10 in 
response to L. monocytogenes infection in vitro is mostly TLR2-dependent and immune 
suppression by phagosome-confined bacteria in vivo is mostly dependent on endosomal TLRs.  
3.2 Introduction 
Listeria monocytogenes is a Gram-positive facultative intracellular pathogen that has been 
widely used as a model to study host immune responses. In mice, primary infection with L. 
monocytogenes induces the generation of adaptive immune responses that are protective against 
subsequent infections and are mediated by CD8+ T cells (150,151). Many innate immune factors 
contribute to control of primary L. monocytogenes infection and development of functional CD8+ 
effector and memory cells (152–155).  
It has been posited that intracytosolic growth of L. monocytogenes is a prerequisite for the 
induction of T cell-mediated immunity because Δhly L. monocytogenes, which does not produce 
the virulence factor Listeriolysin O and cannot escape phagocytic vacuoles, fails to induce robust 
protective immunity (156,157). However, in 2009 Bahjat et al. provided evidence that Δhly L. 
monocytogenes fails to induce robust protective immunity because it induces secretion of IL-10 
early during infection. When IL-10 signaling was inhibited by administration of anti-IL-10 
receptor blocking antibody, Δhly L. monocytogenes induced enhanced protective immunity 
(130). Thus, strains that escape phagocytic vacuoles and grow in the cytosol induce generation of 
protective immunity in part because they avoid inducing IL-10 secretion. 
IL-10 is an anti-inflammatory cytokine that acts on many cell types to downregulate 
inflammation and recruitment of immune cells, ideally limiting immunopathology during the 
resolution of an immune response (158). Infection of wildtype (WT) mice with L. 
monocytogenes results in high levels of serum IL-10 3-4 days post infection (159,160). Mice 
lacking IL-10 clear L. monocytogenes faster than wildtype mice, indicating that IL-10 partially 
suppresses the primary innate immune response to L. monocytogenes (161,162). Importantly, 
though IL-10 is expressed following primary WT L. monocytogenes infection, WT infection 
results in the generation of a robust protective immune response.  
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IL-10 is secreted by many cell types, including macrophages, dendritic cells (DCs), 
neutrophils, NK cells, T-regulatory cells and B cells (158). The IL-10 present in serum 3 to 4 
days after wildtype L. monocytogenes infection of mice is mostly derived from NK cells (159). 
However, Δhly L. monocytogenes induces IL-10 secretion that is detectable four hours after 
infection, and likely comes from macrophages or dendritic cells, which are the first cells infected 
by L. monocytogenes in the spleen (130,137,138). In macrophages, IL-10 expression can be 
triggered by activation of the pattern recognition receptors TLR2, TLR3, TLR4, TLR9 
(158,163). Macrophages secrete high levels of IL-10 in response to the TLR9 agonist CpG, while 
myeloid DCs secrete much less (163). Myeloid DCs can secrete IL-10 upon activation of TLR2, 
TLR4, TLR9, and also the C-type lectins DC-SIGN and Dectin-1 (158,164–166). Thus, there are 
diverse pathways leading to IL-10 secretion. The timing of IL-10 secretion and cell types that 
respond can impact the generation of adaptive immune responses (167).  
The bacterial components and signaling pathways that lead to induction of IL-10 following 
infection with Δhly L. monocytogenes have not been experimentally addressed. In this study, we 
conducted a genetic screen to identify the components of vacuole-confined Δhly L. 
monocytogenes that induce IL-10 secretion from murine bone marrow-derived macrophages. We 
investigated the host signaling pathways that lead to recognition of Δhly L. monocytogenes and 
secretion of IL-10 in macrophages and mice, and how these host signaling pathways affect 
vaccination and immune suppression.  
3.3 Results 
3.3.1 Genetic screen to identify L. monocytogenes mutants that induce enhanced or 
diminished levels of IL-10 
The goal of this study was to identify L. monocytogenes determinants that contribute to 
induction of IL-10 secretion from BMMs. We screened a library of Δhly transposon mutants for 
their ability to induce IL-10 secretion from BMMs. The transposon library was generated in a 
flagellin-negative Δhly background (ΔhlyΔfla) to eliminate the identification of false low-IL-10 
mutants resulting from mutations in flagellar components that reduce infection efficiency. 
Previous work demonstrated that infection of mice with Δhly is immunosuppressive and IL-10 
levels are increased in the serum four hours post-infection (130), while infection with WT leads 
to IL-10 that peaks 3-4 days post-infection (160,161). To determine whether significant IL-10 is 
secreted by L. monocytogenes-infected BMMs four hours post-infection, BMMs were infected 
with Δhly and ΔhlyΔfla L. monocytogenes, and IL-10 was measured from cell supernatants. 
BMMs infected with both Δhly and ΔhlyΔfla L. monocytogenes secreted significantly more IL-
10 than uninfected BMMs four hours post-infection (Fig 3.1A). As L. monocytogenes infection 
leads to significant expression of IL-10 in both BMMs and mice four hours post-infection, we 
analyzed cell supernatants for IL-10 levels four hours post-infection in our screen.  
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Figure 3.1. Screen for Δhly L. monocytogenes mutants that induce enhanced or diminished 
IL-10.  
(A) BMMs were infected with L. monocytogenes lacking LLO (Δhly) or lacking LLO and 
flagellin (ΔhlyΔfla) for four hours. Cell supernatant was collected and IL-10 was measured 
by ELISA. Data shown is representative of two independent experiments. Mean and SD 
are shown. n=3. Data analyzed using Holm-Sidak’s multiple comparisons test. (B) 
Schematic of screen. 6000 ΔhlyΔfla transposon mutants were analyzed for enhanced or 
diminished IL-10 expression in duplicate in a 96-well plate format. 200 mutants were 
selected for secondary screening, and were analyzed for IL-10 in triplicate in a 24-well 
plate format. The mutations from 58 mutants were transduced into a Δhly background. Six 
mutations that resulted in enhanced or diminished IL-10 secretion were identified. (C and 
D) Survival of transposon mutants was quantified in BMMs. Mean and SEM are shown. 
Data is pooled from three coverslips per experiment for three independent experiments. 
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BMMs were infected in duplicate with 6000 gridded ΔhlyΔfla transposon mutants in 96-well 
plates (Screen Scheme in Fig 3.1B). 200 mutants that induced enhanced or diminished IL-10 
levels compared to ΔhlyΔfla were selected for secondary screening. For secondary screening, 
optical density of bacterial cultures was adjusted to eliminate differences in IL-10 secretion due 
to growth differences in broth. 59 of the 200 mutants induced significantly enhanced or 
diminished IL-10 levels compared to ΔhlyΔfla in a 24-well format (Supplemental Table 3.1). 
The transposons in 58 mutants were phage-transduced from the ΔhlyΔfla background into a Δhly 
background. In the Δhly background, only two mutants induced less IL-10 secretion and four 
mutants induced increased IL-10 secretion (Table 3.1).  
 
Diminished IL-10  Gene Annotation IL-10 (% Δhly) Strain Number  
Δlgt lgt 30 DP-L7003 
Lmo2482::Tn lgt 27 DP-L7111 
Lmo0709::Tn hypothetical protein 41 DP-L7080 
Enhanced IL-10  Gene Annotation IL-10 (% Δhly) Strain Number  
ΔpgdAΔoatA pgdA/oatA 263 DP-L7004 
Lmo0415::Tn pgdA 177 DP-L7074 
Lmo2529::Tn ATP synthase F0F1 subunit beta 158 DP-L7112 
Lmo2634::Tn ecfT 140 DP-L7116 
Lmo1291::Tn oatA 139 DP-L7089 
Table 3.1. IL-10 secretion four hours post-infection of BMMs with transposon mutants 
identified by genetic screen and deletion mutants.  
Notably, a mutant with a transposon insertion in phosphatidylglycerol-prolipoprotein 
diacylglyceryl transferase (lgt), induced nearly no IL-10 secretion, though it entered cells and 
survived in cells similar to Δhly (Fig 3.1C). Lgt catalyzes the transfer of a lipid moiety from 
phosphatidylglycerol onto a cysteine residue of prolipoproteins (168–170). The resulting 
lipoproteins are well-known TLR2 agonists. Of the two mutants that induced reduced IL-10 
secretion, we focused on understanding the contribution of lgt to the induction of IL-10 secretion 
from BMMs because the other mutant, which had a transposon insertion in lmo0709, had 
reduced infection capability (Fig 3.1C).  
To confirm the role of lgt in the reduced IL-10 phenotype, an in-frame deletion of lgt was 
generated in a Δhly background. Deletion of lgt did not affect infection efficiency or survival in 
BMMs (Fig 3.2B). Lgt-deletion mutants induced significantly reduced IL-10 secretion from WT 
BMMs compared to Δhly and ΔhlyΔfla. IL-10 levels were restored when lgt was complemented 
in Δhly and ΔhlyΔfla L. monocytogenes under control of the constitutively active pHyper 
promoter (Figure 3.2A). These data indicated that Δhly L. monocytogenes primarily induces IL-
10 secretion in a lipoprotein- and TLR2-dependent manner. 
 
36 
 
 
Figure 3.2.   Δhly-induced IL-10 secretion is largely lgt-dependent and lysis leads to 
increased IL-10 secretion. 
(A) IL-10 secretion from BMMs four hours-post infection.  Mean and SD are shown. Data 
is representative of two independent experiments. Data analyzed using Holm-Sidak’s 
multiple comparison’s test. (B) Survival of lgt deletion mutant in BMMs. Data is 
representative of two independent experiments. Mean and SEM are shown.  (C) IL-10 
secretion from BMMs four hours-post infection.  Mean and SD are shown. Data is 
representative of two independent experiments. Data analyzed using Holm-Sidak’s 
multiple comparison’s test. (B) Survival of ΔhlyΔpgdAΔoatA deletion mutant in BMMs. 
Data is pooled from three coverslips per experiment for three independent experiments. 
Mean and SEM are shown.   
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Of the mutants that induced increased IL-10 secretion, mutations in two of the genes, pgdA 
and oatA, have previously been shown to confer sensitivity to lysozyme (171). We hypothesized 
that these mutants had increased bacterial lysis within host phagosomes, leading to greater 
activation of endosomal nucleic acid-sensing TLRs. Though the mutations did not contribute to a 
noticeable survival defect individually, a strain lacking both pgdA and oatA (ΔhlyΔpgdAΔoatA) 
had a significant survival defect in BMMs (Fig 3.2D), indicative of bacterial death in the 
vacuole. We hypothesized that lysis of bacteria in the phagocytic vacuole could result in release 
of bacterial nucleic acids and activation of nucleic acid-sensing TLRs.  
3.3.2 IL-10 secretion in BMMs 
To analyze the role of TLR2 in secretion of IL-10, we infected macrophages lacking TLR2. 
While infection with Δhly induced significant IL-10 secretion from WT BMMs, Δhly induced 
almost no IL-10 secretion in TLR2-/- BMMs (Fig 3.3A), suggesting that bacterial lipoproteins are 
the major activators of IL-10 secretion in response to infection with Δhly. In contrast, 
ΔhlyΔpgdAΔoatA induced significant levels of IL-10 secretion in TLR2-/- BMMs (Fig 3.3B), 
suggesting that additional bacterial lysis can stimulate a second pathway of IL-10 induction. To 
determine whether this second pathway was the endosomal nucleic-acid sensing TLRs, we 
infected BMMs with a mutation in the endosomal TLR trafficking protein Unc93b1, which is 
defective in endosomal TLR signaling (172). Δhly induced similar amounts of IL-10 in WT and 
Unc93b13d/3d BMMs. (Fig 3.3A). However, ΔhlyΔpgdAΔoatA induced significantly less IL-10 
secretion in Unc93b13d/3d BMMs (Fig 3B).  
To confirm that IL-10 secretion in response to vacuole-confined L. monocytogenes resulted 
from signaling through TLR2 and endosomal TLRs, we infected BMMs with mutations in both 
pathways (TLR2-/-TLR5-/-Unc93b13d/3d). These macrophages secreted IL-10 in response to LPS, 
which is a TLR4 ligand, but not in response to the L. monocytogenes mutants that were tested 
(Fig.3.3C). These results confirmed that IL-10 secretion from BMMs results from signaling 
through TLR2 and endosomal TLRs. 
38 
 
  
 
 
Figure 3.3 IL-10 secretion from BMMs in response to L. monocytogenes infection requires 
TLR2 and endosomal TLR signaling.  
WT, TLR2-/-, Unc93b1-/-, and TLR2-/-TLR5-/-Unc93b13d/3d BMMs were infected with Δhly 
L. monocytogenes (A) or ΔhlyΔpgdAΔoatA L. monocytogenes (B). Cell supernatant was 
harvested four hours post infection and IL-10 was measured by ELISA. Data shown is 
representative of two independent experiments. Means were compared to WT using Holm-
Sidak’s Multiple Comparisons test. (C) TLR2-/-TLR5-/-Unc93b13d/3d BMMs were infected 
with the indicated strains of L. monocytogenes, or treated with LPS, a TLR4 agonist; CpG, 
a TLR9 agonist; or Pam2CSK4, a TLR2 agonist. Data shown is pooled from two 
independent experiments. Data analyzed using Holm-Sidak’s Multiple Comparisons test.  
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3.3.3 Cytokine secretion in mice 
 To determine whether secretion of IL-10 in mice was dependent on TLR2 and/or 
endosomal TLRs, mice were infected intravenously and serum IL-10 four hours post-infection 
was quantified (Fig 3.4A-D). Infection of WT mice with Δhly resulted in significant levels of IL-
10. Unlike in BMMs, Δhly also induced significant amounts of IL-10 in TLR2-/- mice (Fig 3.4B), 
suggesting that bacterial lipoproteins were not the dominant IL-10-inducing molecules in mice. 
In contrast, IL-10 secretion in Unc93b13d/3d or TLR2-/-TLR5-/-Unc93b13d/3d mice was almost zero 
(Fig 3.4C and 3.4D). Together, these results indicate that endosomal TLRs are the primary IL-10 
signaling pathways that respond to Δhly infection in mice.  
 One function of IL-10 signaling is to limit proinflammatory cytokine secretion. To 
investigate the relationship between TLRs and proinflammatory cytokine signaling, serum levels 
of MCP-1 were quantified 24 hours post-infection (Fig 3.4E-H). In WT mice, Δhly did not 
induce secretion of MCP-1, while ΔactA, a strain of L. monocytogenes that escapes the 
phagocytic vacuole and replicates in the host cell cytosol, induced significant amounts of MCP-1 
(Fig 3.4E). Likewise, ΔactA, but not Δhly, induced significant MCP-1 secretion in TLR2-/- mice 
(Fig 3.4F-H). Because early IL-10 expression is thought to limit later expression of 
proinflammatory cytokines, we hypothesized that Δhly would induce proinflammatory cytokines 
in Unc93b13d/3d and TLR2-/-TLR5-/-Unc93b13d/3d mice. However, MCP-1 was not induced in 
response to Δhly background strains in Unc93b13d/3d and TLR2-/-TLR5-/-Unc93b13d/3d mice (Fig 
3.4G and 3.4H).  These results indicated that endosomal TLR signaling may be required for Δhly 
to induce a proinflammatory cytokine response. 
Vaccination of mice with ΔactA has previously been shown to result in high levels of 
proinflammatory cytokines, whereas vaccination of mice with Δhly induced high levels of IL-10 
and low levels of proinflammatory cytokines in WT mice. Strikingly, co-administration of ΔactA 
and Δhly resulted in high levels of IL-10 and low levels of proinflammatory cytokines in WT 
mice (130), suggesting that Δhly suppresses the proinflammatory responses usually induced by 
ΔactA. We analyzed the levels of MCP-1 in serum as a measure of the proinflammatory cytokine 
response. It was previously reported that ΔactA induced significant amounts of MCP-1 in WT 
mice, but that co-administration of ΔactA with 1000-fold more Δhly CFU resulted in reduced 
expression of MCP-1 (130). Co-administration of ΔactA and Δhly did not result in significant 
MCP-1 secretion in WT mice, consistent with previous findings. Co-administration of ΔactA and 
Δhly in TLR2-/- mice also did not result in significant MCP-1 secretion, suggesting that 
immunosuppression by Δhly is not mediated by TLR2 signaling (Fig 3.4E and 3.4F). However, 
co-administration of ΔactA and Δhly resulted in significant secretion of MCP-1 in Unc93b13d/3d 
and TLR2-/-TLR5-/-Unc93b13d/3d mice (Fig 3.4G and 3.4H). These results indicated that 
suppression of proinflammatory cytokines by Δhly is mediated by Unc93b1-dependent TLRs.  
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Figure 3.4. IL-10 secretion in mice is dependent on endosomal TLR signaling.  
Mice were infected with 108 CFU of Δhly, 105 CFU of ΔactA, or a combination of 108 
CFU of Δhly and 105 CFU of ΔactA. WT C57BL/6J mice (A and E), TLR2-/- (B and F), 
Unc93b13d/3d (C and G), and TLR2-/-TLR5-/-Unc93b13d/3d (D and H) were infected. Serum 
measurements of IL-10 four hours post-infection (A-D) and MCP-1 twenty-four hours 
post-infection (E-H). Data is pooled from two to four independent experiments. Bar 
represents the median. Data analyzed using Holm-Sidak’s Multiple Comparisons test. 
 
3.3.4 Suppression of adaptive immunity 
 To investigate the relationship between IL-10 signaling pathways and suppression of 
adaptive immunity, co-vaccination experiments were performed in which ΔactA and 1000-fold 
more Δhly CFU were injected simultaneously as described in (130) (Fig 3.5). In WT mice, 
vaccination with ΔactA leads to the induction of robust adaptive immunity that can nearly clear a 
subsequent lethal dose of WT L. monocytogenes. However, the immunity induced by ΔactA is 
suppressed two-logs by co-administration of Δhly (Fig 3.5A). This suppression was previously 
shown to depend on IL-10 (157). We hypothesized that Δhly would suppress immunity in WT 
and TLR2-/- mice, in which we observed significant secretion of IL-10 and low levels of MCP-1, 
but not in Unc93b13d/3d or TLR2-/-TLR5-/-Unc93b13d/3d mice, in which we observed no IL-10 and 
high levels of MCP-1. That was indeed the case, as we observed 2-logs of immune suppression 
in WT and TLR2-/- mice (Fig 3.5A and 3.5B). However, in Unc93b13d/3d or TLR2-/-TLR5-/-
Unc93b13d/3d mice co-administration of ΔactA with Δhly did not reduce protective immunity (Fig 
3.5C and 3.5D). Thus, vacuole-confined L. monocytogenes induce IL-10 in mice primarily 
through endosomal TLRs which leads to suppression of adaptive immunity.  
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Figure 3.5. Immune suppression is primarily mediated by endosomal TLR signaling.  
Mice were infected with 108 CFU of Δhly, 105 CFU of ΔactA, or a combination of 108 
CFU of Δhly and 105 CFU of ΔactA. WT C57BL/6J mice (A), TLR2-/- (B), Unc93b13d/3d 
(C), and TLR2-/-TLR5-/-Unc93b13d/3d (D) were infected. Four-to-eight weeks post-
vaccination, mice were challenged with 5x105 WT L. monocytogenes. CFU from the 
spleen were enumerated three days post-challenge. Data is pooled from two to five 
independent experiments. Bar represents the median. Data analyzed using an unpaired t 
test.  
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3.4 Discussion 
The results of this study show that the secretion of IL-10 by BMMs is largely mediated by 
TLR2-detection of bacterial lipoproteins. However, analysis of mutants that induced enhanced 
IL-10 revealed a second pathway that was dependent on bacterial lysis triggering nucleic-acid 
sensing TLRs in the phagosome. In mice, nucleic acid-sensing TLRs were the dominant trigger 
of IL-10 secretion.  
The differences in TLR contributions to IL-10 expression in BMMs compared to mice likely 
reflects the differing abilities of macrophages to kill and degrade L. monocytogenes. In BMMs, 
which are differentiated and cultured ex vivo, Δhly L. monocytogenes cannot grow but are not 
efficiently killed (Fig 3.2B). In contrast, peritoneal macrophages taken directly from mice kill 
vacuole-confined bacteria (173). In the absence of bacterial killing, bacterial lipoproteins are the 
most abundant TLR stimulus. In mice, we surmise that increased bacterial killing leads to release 
of nucleic acids and lipoproteins that are sensed by endosomal TLRs and TLR2, respectively. 
The results of our analysis of BMMs indicates that TLR2 and Unc93b1-dependent TLRs 
represent two independent pathways that lead to IL-10 expression. However, our data in mice 
indicates that TLR2-signaling does not contribute to IL-10 expression to the same extent as 
endosomal TLRs. Unc93b13d/3d mice retain signaling through TLR2, but did not express 
significant IL-10 following infection with Δhly (Fig 3.4C). In contrast, TLR2-deficient mice 
expressed significant IL-10 following infection with Δhly (Fig 3.4B). This IL-10 was sufficient 
to inhibit the generation of protective immunity by ΔactA, indicating that IL-10 downstream of 
endosomal TLRs is the major mediator of immune suppression.  
It was shown previously that administration of anti-IL-10 receptor blocking antibody 
restored the protective potential of Δhly. However, in this study we observed that, in mice with a 
defect in endosomal TLR signaling, vaccination with Δhly L. monocytogenes did not induce IL-
10 secretion but still did not lead to the generation of a protective immune response. A 
proinflammatory response was also not induced in Unc93b1 mutant mice following vaccination 
with Δhly, which may explain why a protective immune response was not generated. The 
differences in immunity following vaccination of WT mice with Δhly and anti-IL10R blocking 
antibody and vaccination of Unc93b1 mutant mice with Δhly may reflect the fact that anti-IL10R 
blocking antibody only blocks IL-10 signaling, while mice with defects in endosomal TLR 
signaling may not be able to generate a proinflammatory response to Δhly and are thus inhibited 
in generating protective immunity. 
Although the results of our study suggest that recognition of bacterial lipoproteins by TLR2 
is not the primary reason for induction of IL-10, TLR2 is still an important host receptor to 
consider for the development of bacterial vaccine delivery systems. L. monocytogenes expresses 
over 30 diacylated lipoproteins that are recognized by TLR2/TLR6 dimers (174–177). Deletion 
of lgt in WT L. monocytogenes results in delayed secretion of proinflammatory cytokines, but 
only a modest virulence defect in mice (178). Thus, removing lipoproteins is a promising 
strategy for improving L. monocytogenes-based vaccines by changing the cytokine response 
without significantly affecting bacterial fitness. One potential method of modulating the response 
to lipoproteins that has not been explored in L. monocytogenes is the engineering of L. 
monocytogenes lipoproteins with different acylation states. Triacylated lipoproteins are 
recognized by TLR2/TLR1 heterodimers and elicit a different inflammatory response than 
diacylated lipoproteins (179). More recently, three additional classes of lipoprotein modification 
with differing abilities to stimulate TLR2 have been described in Gram-positive bacteria (174). It 
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would be interesting to investigate the contributions of differently acylated lipoproteins to the 
development of adaptive immunity. Modulating the expression of individual lipoproteins could 
also impact the immune response. It is not clear whether all L. monocytogenes lipoproteins 
contribute to TLR2 activation, or whether L. monocytogenes has a subset of lipoproteins that 
specifically activate TLR2. Though the lipid portion of lipoproteins mediates binding of 
lipoproteins to TLR2, the sequence of the attached peptides affects the ability of lipoproteins to 
differentially stimulate cytokine secretion (180). Therefore, increasing or decreasing the 
expression of specific lipoproteins could be a strategy for fine-tuning the proinflammatory 
immune response. In addition, TLR2 is traditionally considered a cell-surface-localized TLR, but 
there is evidence that lipoproteins can activate TLR2 signaling in the endosomal compartment 
and that signaling from the endosomal compartment can have different effects than from the 
plasma membrane (181–185). How specific lipoproteins and acylation state contribute to 
activation of TLR2, and how TLR2 activation on the cell surface versus in the lysosome 
contributes to the cytokine response is relevant for the development of bacterial vaccine vectors 
and warrants further study.  
The results of this study indicated that, in mice, endosomal TLRs sense vacuole-confined L. 
monocytogenes, resulting in the secretion of IL-10. In our genetic screen, we identified mutants 
that had increased IL-10 secretion in WT, TLR2-/-, and Unc93b13d/3d macrophages (Supplemental 
Table 3.2), including transposon insertions in pgdA and oatA, genes for which mutations have 
previously been shown to confer increased lysozyme sensitivity (186). Enhanced IL-10 
expression in response to L. monocytogenes mutants was dependent on both TLR2 and 
endosomal TLRs, as no mutants induced detectable IL-10 secretion in TLR2-/-TLR5-/-
Unc93b13d/3d BMMs (Supplemental Table 3.2), suggesting that bacterial lysis releases nucleic 
acids and lipoproteins that are both sensed by the cell. Though we did not observe a decrease in 
colony forming units of Δhly or the pgdA or oatA transposon mutants in macrophages, 
ΔhlyΔpgdAΔoatA died rapidly (Fig 3.1D). Therefore, the individual mutants for which we 
observed increased IL-10 likely have minor increases in lysis that were not easily detected by 
CFU. However, in combination, the pgdA and oatA mutations synergized to yield a mutant that 
was extremely susceptible to lysis in cells and potently induced IL-10. Importantly, these data 
suggest that low-level lysis can be detected by TLRs and lead to significant changes in cytokine 
secretion.   
 The majority of mutants identified in our screen induced increased IL-10 secretion. 
Strikingly, while 50 mutants that induced increased IL-10 secretion were identified in our initial 
screen in ΔhlyΔfla L. monocytogenes (Supplemental Table 3.1), only 4 of those mutants induced 
significantly increased IL-10 secretion in a Δhly background (Supplemental Table 3.2). It is 
possible that Δhly may be slightly more sensitive to lysis compared to ΔhlyΔfla. Flagellar 
secretion systems require the activity of hydrolases or lytic transglycosylases to degrade 
peptidoglycan to allow insertion of flagellar components (187,188). Thus it is reasonable to 
suspect that the cell wall of Δhly is more fragile than that of ΔhlyΔfla and lyses more inside 
vacuoles due to the activity of a flagella-associated peptidoglycan-degrading enzymes. An 
increase is the basal levels of lysis would increase the basal levels of IL-10 and potentially mask 
the effects of other mutations that slightly increase lysis. The results of this study suggest that 
any mutation that promotes bacterial lysis within a phagosome will lead to IL-10 induction. 
In this study, we did not investigate whether a particular endosomal nucleic-acid sensing 
TLR is responsible for induction of IL-10, whether there is redundancy, or whether there is 
synergism. It is likely that all nucleic-acid sensing TLRs can be activated following bacterial 
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lysis. Bacterial lysis should lead to the release of bacterial contents including: mRNA that can 
activate TLR7/8, unmethylated CpG chromosomal DNA that can activate TLR9, and ribosomal 
RNA that can activate TLR13 (189). Although TLR3 could also recognize double-stranded RNA 
released upon bacterial lysis, it likely does not to contribute to IL-10 secretion because it was 
previously demonstrated that IL-10 secretion in response to vacuole-confined L. monocytogenes 
is dependent on the signaling adapter MyD88, and TLR3 uses the signaling adapter TRIF 
(130,189). It has been previously suggested that bacterial mRNA represents a signature of 
bacterial viability (190). Perhaps, then, simultaneous recognition of multiple types of nucleic 
acid by multiple TLRs is indicative of nonviable bacteria.  
 The observation that the immune system responds more robustly to bacteria that are alive 
compared to bacteria that are dead led to the idea that the immune system has ways of 
monitoring bacterial viability (190–192). Many signals have been proposed to be “PAMPs per 
vita” or “vita-PAMPs”—signatures of microbial viability. DNA and RNA have been proposed as 
possible “PAMP postmortem” (PAMP-PM). In line with the idea of recognition of postmortem 
PAMPs, the secretion of IL-10 following infection of mice with Δhly could represent a strategy 
to prevent an unnecessary immune response to bacteria that are already dead, and thus do not 
pose a threat. To that end, nucleic acid-sensing TLRs are better suited for assessing bacterial 
viability than TLR2, because living bacteria do not normally release nucleic acids, especially 
chromosomal DNA, into the surrounding environment. Signaling through nucleic-acid sensing 
TLRs thus more accurately indicates that a bacterium is dead than sensing of lipoproteins, which 
can be detected whether a pathogen is alive or dead.  
Induction of IL-10 secretion is an important factor to consider in the development of 
bacterial vaccine vectors. Both live and dead bacterial vaccine vectors have the potential to 
induce IL-10 secretion. The kinetics of IL-10 secretion may play an important role in 
determining whether a vaccine will be effective or not. In our study, we identified sensing of 
nucleic acids as the primary signal for IL-10 induction. For the development of future vaccine 
strains, strategies to minimize IL-10 induction and immune suppression should be considered. 
For example, mutations that modify the cell wall could be employed to reduce bacterial death in 
phagosomes. Also, as suggested above, simply deleting flagellin may decrease bacteriolysis. 
Mutations could also be made to alter lipoproteins and enhance TLR2 activation and 
proinflammatory cytokine. In combination, modifications that reduce IL-10 secretion and 
modulate proinflammatory cytokines downstream of TLR2 may yield a vaccine strain that has 
increased potency.  
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3.5 Materials and Methods 
Strain Construction 
In-frame deletion of genes was performed using allelic exchange as previously described 
(193). ΔhlyΔfla was generated by deleting hly in a ΔflaA strain (DP-L5986). ΔhlyΔlgt was 
generated by deleting lgt in a Δhly strain (DP-L2161). ΔhlyΔflaΔlgt was generated by deleting 
lgt in a ΔhlyΔfla strain. ΔhlyΔpgdAΔoatA was generated by deleting hly in a ΔpgdAΔoatA strain 
(DP-L5220). ΔhlyΔflaΔlgt was generated by deleting lgt in a ΔhlyΔfla strain. The lgt 
complemented strains were generated by integrating a pPL2 vector encoding lgt under control of 
the pHyper promoter (pPL2t-pHyper-lgt) into the L. monocytogenes genome and selecting for 
tetracycline-resistant transconjugates (194).  
 
Transposon Library Generation 
A transposon library was generated in ΔhlyΔfla as previously described (195). Transposon 
mutations were transduced into Δhly using U153 phage as previously described (196). 
 
Bone Marrow-Derived Macrophage Culture 
BMM growth media was prepared using high glucose DMEM (Thermo Fisher Scientific) 
with 20% Fetal Bovine Serum (Seradigm), 1% L-glutamine (Corning), 1% Sodium pyruvate 
(Corning), 14mM 2-Mercaptoethanol (Gibco), and 10% 3T3 cell supernatant (from M-CSF-
producing 3T3 cells).  
 
Intracellular Survival/Growth of L. monocytogenes in BMMs 
3 × 106 BMMs were plated in 60 mm non-TC-treated Petri dishes with 14 12mm glass 
coverslips in each dish. Dishes were infected with 5 x 105 CFU (MOI=0.17) and intracellular 
growth curves were performed as described previously (96). 
 
Quantification of IL-10 from BMMs – 96-well format 
2.6 x 105 BMMs in 200 µL BMM growth media were seeded into wells of a 96-well plate. 
Bacteria were grown in 1 mL Brain-Heart Infusion Broth containing 200g/mL streptomycin in 
96-well deep well plates at 30C. Prior to infection, bacteria were pelleted by centrifugation and 
resuspended in 1 mL PBS. Wells were infected with 8 L of resuspended bacteria. Plates were 
infected in duplicate. 30 minutes post-infection, cells were washed with warm PBS, and BMM 
growth media with 50 µg/mL gentamicin was added. Supernatants were collected and frozen at -
80C until used for analysis. For quantification of IL-10, Mouse IL-10 DuoSet ELISA (R&D 
Systems) was performed according to manufacturer’s instructions.  
 
Quantification of IL-10 from BMMs – 24-well format 
6 x 105 – 7 x 105 BMMs in 500 µL BMM growth media were seeded into wells of a 24-well 
plate. Bacteria were grown overnight at 30C at a slant without shaking in 3 mL Brain-Heart 
Infusion Broth containing 200g/mL streptomycin. Cultures were then pelleted by 
centrifugation, and resuspended in phosphate-buffered solution (PBS) to an optical density of 
2.0. Wells were infected with 20µL of bacteria, approximately 8 x 107 CFU (MOI=120). Three 
wells were infected for each bacterial strain. 30 minutes post-infection, cells were washed with 
warm PBS, and BMM growth media with 50 µg/mL gentamicin was added. Supernatants were 
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collected and frozen at -80C until used for analysis. For quantification of IL-10, Mouse IL-10 
DuoSet ELISA (R&D Systems) was performed according to manufacturer’s instructions.  
 
Animal Use Ethics Statement 
All animal work was done in strict accordance with university regulations. Protocols were 
reviewed and approved by the Animal Care and Use Committee at the University of California, 
Berkeley AUP-2016-05-8811. 
 
Mice 
C57BL/6J mice were purchased from Jackson Laboratories. TLR2-/-, Unc93b13d/3d, and 
TLR2-/-TLR5-/-Unc93b13d/3d were a gift from Greg Barton and were bred in our facility. 
 
Quantification of cytokines from serum 
Eight-to-twelve week old female mice were injected via the tailvein with 108 CFU of Δhly 
background strains or 105 CFU ΔactA. Bacteria were grown overnight at 30C at a slant without 
shaking in Brain-Heart Infusion Broth containing 200g/mL streptomycin. Bacteria were then 
backdiluted 1:20 and grown at 37C shaking for about two hours until they reached an optical 
density of 0.5. Cultures were pelleted and resuspended in PBS to the appropriate concentration, 
such that mice were infected with 200µL. Four and twenty-four hours post infection, blood was 
collected from the submandibular vein into Microtainer tubes with serum separator additive 
(BD). Blood was left to rest for 30 minutes before tubes were centrifuged and serum was 
collected. Collected serum was stored at -20C until analysis. Analysis of cytokines from serum 
was performed using Mouse Inflammation Cytokine Bead Arrays (BD, Cat. 552364). Data was 
analyzed using FlowJo.  
 
Vaccination and Immune Suppression 
Eight-to-twelve week old female mice were vaccinated intravenously via the tailvein with 
108 CFU of Δhly background strains or 105 CFU ΔactA. Bacteria were grown overnight at 30C 
at a slant without shaking in Brain-Heart Infusion Broth containing 200g/mL streptomycin. 
Bacteria were then backdiluted 1:20 and grown at 37C shaking for about two hours until they 
reached an optical density of 0.5. Cultures were pelleted and resuspended in PBS to the 
appropriate concentration, such that mice were vaccinated with 200 µL. Eight weeks post-
vaccination, mice were challenged with 5 x 104 CFU WT L. monocytogenes. Three days post-
challenge, mice were euthanized and CFU in the spleens and livers were enumerated.  
 
Statistical Analysis 
Data were analyzed using GraphPad Prism 8. For mouse CFU experiments, data was log-
transformed prior to performing statistical analysis. * indicates P <0.05; ** indicates P <0.01, 
*** indicates P <0.001, **** indicates P <0.0001; ns indicates no statistical significance.  
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Supplemental Figure 3.1. Survival of transposon mutants in WT BMMs.  
Survival of transposon mutants was quantified in BMMs. Mean and SEM are shown. Data 
is pooled from three coverslips per experiment for three independent experiments. 
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Supplemental Table 3.1. IL-10 secretion of transposon mutants in ΔhlyΔfla background 
compared to ΔhlyΔfla. 
Lmo Gene Annotation Mean IL-10 (% 
ΔhlyΔfla IL-10) 
Standard 
Deviation 
0095 promoter region of lmo0095 162 14 
0286 pyridoxal phosphate-dependent 
aminotransferase 
202 25 
0331 LPXTG-motif cell wall anchor domain-
containing protein 
137 6 
0333 inlI, LPXTG-motif cell wall anchor domain-
containing protein 
165 28 
0367 deferrochelatase/peroxidase EfeB  142 7 
0371 GntR family transcriptional regulator 77 8 
0415 Peptidoglycan/xylan/chitin deacetylase, 
PgdA/CDA1 family 
172 8 
0497 Glycosyl transferase family 2 151 24 
0524 sulfate transporter 134 1 
0580 Phospholipase/Carboxylesterase 184 7 
0635 HAD family hydrolase 153 17 
Lmo0671-
lmo0672 
Uncharacterized membrane protein YhaH, 
DUF805 family 
153 12 
0709 Hypothetical protein 68 4 
0769 alpha-1,6-mannanase 226 37 
0785 sigma54-associated activator ManR 131 2 
0842 putative peptidoglycan bound protein (LPXTG 
motif) 
171 28 
0848 amino acid ABC transporter ATP-binding 
protein 
171 19 
0954 promoter region of lmo0954 73 6 
1080 teichoic acid biosynthesis protein GgaB 64 13 
1131 ABC transporter ATP-binding protein 245 14 
1140 hypothetical protein 161 1 
1241 hypothetical protein 158 10 
1291 (oatA) acetyltransferase to YrhL 158 15 
1293 glycerol-3-phosphate dehydrogenase, glpD 77 8 
1296 GTPase HflX 142 16 
1366 23S rRNA (cytidine1920-2'-O)/16S rRNA 
(cytidine1409-2'-O)-methyltransferase 
135 2 
1395 protein RodZ, contains Xre-like HTH and 
DUF4115 domains 
126 4 
1429 energy-coupled thiamine transporter ThiT 125 9 
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1499 endolytic transglycosylase MltG 153 26 
1652 multidrug ABC transporter permease/ATP-
binding protein 
130 7 
1695 mprF 145 17 
1742 adeC 154 25 
1775 promoter region, purE, 
phosphoribosylaminoimidazole carboxylase 
catalytic subunit 
144 2 
1799 putative peptidoglycan bound protein (LPXTG 
motif) 
252 11 
1835 pyrAB 213 29 
1843 RluA family pseudouridine synthase 153 19 
1877 formyl-tetrahydrofolate synthetase 151 11 
1956 Fur family transcriptional regulator, ferric 
uptake regulator 
77 3 
2027 putative cell surface protein, similar to 
internalin proteins  
198 10 
2079 hypothetical protein 78 8 
2128 transcriptional regulator, LacI family 178 11 
2229 penicillin-binding protein 2A 141 10 
2287 putative tape-measure [Bacteriophage A118] 183 5 
2389 NADH dehydrogenase 146 18 
2482 (lgt) prolipoprotein diacylglyceryl transferase 9 1 
2529 ATP synthase F0F1 subunit beta 159 22 
2530 atpG 146 27 
2531 ATP synthase F0F1 subunit alpha 16 2 
2581 promoter region of ABC transporter permease 154 13 
2634 energy-coupling factor transporter 
transmembrane protein EcfT 
164 23 
2634 energy-coupling factor transporter 
transmembrane protein EcfT 
135 8 
2641 heptaprenyl diphosphate synthase 163 19 
2720 acyl--CoA ligase 161 29 
2757 DNA helicase RecQ 152 5 
2760 ABC transporter ATP-binding protein 174 19 
2816 Sugar phosphate permease 132 11 
2835 xylose isomerase 172 20 
2835 xylose isomerase 165 1 
2854 Membrane protein insertase YidC 2 156 30 
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Supplemental Table 3.2. IL-10 secretion of transposon mutants in Δhly background 
compared to Δhly. 
Lmo WTα Sign.β TLR2α Sign.β Unc93b13d/3d α Sign.β TLR2-/-TLR5-/-
Unc93b13d/3d α 
0005 88 ns 114 ns 125 ns µ 
0286 118 ns 96 ns 105 ns µ 
0331 97 ns 131 ns 128 ns µ 
0333 119 ns 111 ns 130 ns µ 
0367 116 ns 134 ns 142 ns µ 
0371 101 ns 177 ** 130 * µ 
0415 177 **** 493 **** 174 **** µ 
0497 89 ns 108 ns 116 ns µ 
0524 108 ns 136 ns 155 * µ 
0580 96 ns 131 ns 115 ns µ 
0635 127 ns 139 ns 142 ns µ 
Lmo0671
-lmo0672 
104 ns 128 ns 117 ns µ 
0709 41 **** 64 ns 77 ns µ 
0769 133 ns 185 ns 144 ** µ 
0785 120 ns 118 ns 128 ns µ 
0842 170 ns 153 ns 175 **** µ 
0848 85 ns 90 ns 112 ns µ 
0954 90 ns 100 ns 113 ns µ 
1131 114 ns 148 ns 152 *** µ 
1140 124 ns 106 ns 124 ns µ 
1241 109 ns 135 ns 121 ns µ 
1291 139 ** 327 **** 184 **** µ 
1293 122 ns 137 ns 109 ns µ 
1296 138 ns 121 ns 143 * µ 
1366 102 ns 128 ns 145 * µ 
1395 91 ns 113 ns 146 ns µ 
1429 124 ns 184 ** 127 ns µ 
1499 114 ns 137 ns 115 ns µ 
1652 97 ns 148 * 148 ns µ 
1695 99 ns 86 ns 179 *** µ 
1742 126 ns 152 ns 176 *** µ 
1775 107 ns 200 *** 136 ns µ 
1799 108 ns 134 ns 137 ns µ 
1835 135 ns 103 ns 165 **** µ 
1843 127 ns 154 ns 124 ns µ 
1877 125 ns 133 ns 123 ns µ 
1956 97 ns 207 **** 129 ns µ 
2027 118 ns 147 * 114 ns µ 
2079 73 ns 139 ns 131 ns µ 
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2128 119 ns 133 ns 131 * µ 
2229 122 ns 133 ns 148 **** µ 
2287 114 ns 108 ns 132 ns µ 
2389 88 ns 162 ns 112 ns µ 
2482 27 **** 162 ** 4 **** µ 
2529 158 * 221 **** 162 ** µ 
2530 209 ns 251 **** 118 ns µ 
2531 113 ns 212 *** 106 ns µ 
2581 96 ns 177 * 160 *** µ 
2634 140 * 145 * 154 ** µ 
2634 185 ns 342 * 158 ** µ 
2641 95 ns 194 *** 135 ns µ 
2720 89 ns 105 ns 113 ns µ 
2757 108 ns 105 ns 156 ns µ 
2760 95 ns 100 ns 124 ns µ 
2816 102 ns 170 ns 116 ns µ 
2835 90 ns 151 ns 109 ns µ 
2854 136 ns 134 ns 167 ns µ 
Values reported are percent IL-10 normalized to 100% Δhly IL-10. α BMM background. 
µIL-10 secretion <80pg/mL. βΔhly transposon mutant IL-10 values were compared to Δhly 
IL-10 values using Dunnett’s multiple comparisons test. * indicates these values are 
statistically significant, with a p-value <0.05; ** indicates a p-value <0.01; *** indicates 
a p-value <0.001; **** indicates a p-value <0.0001; ns indicates no statistical 
significance. 
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Supplemental Table 3.3. List of Strains. 
Strain name 
Strain 
background 
Lmo of 
Gene with 
Transposon 
Insertion 
Integrated 
Plasmid 
Strain 
Number Reference 
Δhly Δhly - - DP-L2161  (2) 
ΔflaA ΔflaA     DP-L5986  This study 
hly knockout plasmid E. coli - - DP-L2154  (2) 
ΔhlyΔfla ΔhlyΔfla - - DP-L7001 This study 
lgt knockout plasmid E. coli - - DP-E7002 This study 
ΔhlyΔlgt ΔhlyΔlgt - - DP-L7003 This study 
ΔpgdAΔoatA ΔpgdAΔoatA - - DP-L5220 (171) 
ΔhlyΔpgdAΔoatA ΔhlyΔpgdAΔoatA - - DP-L7004 This study 
ΔhlyΔflaΔlgt ΔhlyΔflaΔlgt - - DP-L7005 This study 
pPL2t-pHyper-lgt E. coli - - DP-E7006 This study 
ΔhlyΔlgt + lgt ΔhlyΔlgt - 
pPL2t-
pHyper-lgt DP-L7007 This study 
ΔhlyΔflaΔlgt + lgt ΔhlyΔflaΔlgt - 
pPL2t-
pHyper-lgt DP-L7008 This study 
ΔactA ΔactA - - DP-L4029  (194) 
  ΔhlyΔfla Lmo0095   DP-L7009 This study 
  ΔhlyΔfla Lmo0286   DP-L7010 This study 
  ΔhlyΔfla Lmo0331   DP-L7011 This study 
  ΔhlyΔfla Lmo0333   DP-L7012 This study 
  ΔhlyΔfla Lmo0367   DP-L7013 This study 
  ΔhlyΔfla Lmo0371   DP-L7014 This study 
  ΔhlyΔfla Lmo0415   DP-L7015 This study 
  ΔhlyΔfla Lmo0497   DP-L7016 This study 
  ΔhlyΔfla Lmo0524   DP-L7017 This study 
  ΔhlyΔfla Lmo0580   DP-L7018 This study 
  ΔhlyΔfla Lmo0635   DP-L7019 This study 
  ΔhlyΔfla 
Intergenic; 
Lmo0671- 
Lmo0672 
  
DP-L7020 This study 
  ΔhlyΔfla Lmo0709   DP-L7021 This study 
  ΔhlyΔfla Lmo0769   DP-L7022 This study 
  ΔhlyΔfla Lmo0785   DP-L7023 This study 
  ΔhlyΔfla Lmo0842   DP-L7024 This study 
  ΔhlyΔfla Lmo0848   DP-L7025 This study 
  ΔhlyΔfla Lmo0954   DP-L7026 This study 
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  ΔhlyΔfla Lmo1080   DP-L7027 This study 
  ΔhlyΔfla Lmo1131   DP-L7028 This study 
  ΔhlyΔfla Lmo1140   DP-L7029 This study 
  ΔhlyΔfla Lmo1241   DP-L7030 This study 
  ΔhlyΔfla Lmo1291   DP-L7031 This study 
  ΔhlyΔfla Lmo1293   DP-L7032 This study 
  ΔhlyΔfla Lmo1296   DP-L7033 This study 
  ΔhlyΔfla Lmo1366   DP-L7034 This study 
  ΔhlyΔfla Lmo1395   DP-L7035 This study 
  ΔhlyΔfla Lmo1429   DP-L7036 This study 
  ΔhlyΔfla Lmo1499   DP-L7037 This study 
  ΔhlyΔfla Lmo1652   DP-L7038 This study 
  ΔhlyΔfla Lmo1695   DP-L7039 This study 
  ΔhlyΔfla Lmo1742   DP-L7040 This study 
  ΔhlyΔfla Lmo1775   DP-L7041 This study 
  ΔhlyΔfla Lmo1799   DP-L7042 This study 
  ΔhlyΔfla Lmo1835   DP-L7043 This study 
  ΔhlyΔfla Lmo1843   DP-L7044 This study 
  ΔhlyΔfla Lmo1877   DP-L7045 This study 
  ΔhlyΔfla Lmo1956   DP-L7046 This study 
  ΔhlyΔfla Lmo2027   DP-L7047 This study 
  ΔhlyΔfla Lmo2079   DP-L7048 This study 
  ΔhlyΔfla Lmo2128   DP-L7049 This study 
  ΔhlyΔfla Lmo2229   DP-L7050 This study 
  ΔhlyΔfla Lmo2287   DP-L7051 This study 
  ΔhlyΔfla Lmo2389   DP-L7052 This study 
  ΔhlyΔfla Lmo2482   DP-L7053 This study 
  ΔhlyΔfla Lmo2529   DP-L7054 This study 
  ΔhlyΔfla Lmo2530   DP-L7055 This study 
  ΔhlyΔfla Lmo2531   DP-L7056 This study 
  ΔhlyΔfla Lmo2581   DP-L7057 This study 
  ΔhlyΔfla Lmo2634   DP-L7058 This study 
  ΔhlyΔfla Lmo2634   DP-L7059 This study 
  ΔhlyΔfla Lmo2641   DP-L7060 This study 
  ΔhlyΔfla Lmo2720   DP-L7061 This study 
  ΔhlyΔfla Lmo2757   DP-L7062 This study 
  ΔhlyΔfla Lmo2760   DP-L7063 This study 
  ΔhlyΔfla Lmo2816   DP-L7064 This study 
  ΔhlyΔfla Lmo2835   DP-L7065 This study 
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  ΔhlyΔfla Lmo2835   DP-L7066 This study 
  ΔhlyΔfla Lmo2854   DP-L7067 This study 
  Δhly Lmo0095   DP-L7068 This study 
  Δhly Lmo0286   DP-L7069 This study 
  Δhly Lmo0331   DP-L7070 This study 
  Δhly Lmo0333   DP-L7071 This study 
  Δhly Lmo0367   DP-L7072 This study 
  Δhly Lmo0371   DP-L7073 This study 
Δhly pgdA::Tn Δhly Lmo0415   DP-L7074 This study 
  Δhly Lmo0497   DP-L7075 This study 
  Δhly Lmo0524   DP-L7076 This study 
  Δhly Lmo0580   DP-L7077 This study 
  Δhly Lmo0635   DP-L7078 This study 
  Δhly 
Intergenic; 
Lmo0671- 
Lmo0672 
  
DP-L7079 This study 
Δhly lmo0709::Tn Δhly Lmo0709   DP-L7080 This study 
  Δhly Lmo0769   DP-L7081 This study 
  Δhly Lmo0785   DP-L7082 This study 
  Δhly Lmo0842   DP-L7083 This study 
  Δhly Lmo0848   DP-L7084 This study 
  Δhly Lmo0954   DP-L7085 This study 
  Δhly Lmo1131   DP-L7086 This study 
  Δhly Lmo1140   DP-L7087 This study 
  Δhly Lmo1241   DP-L7088 This study 
Δhly oatA::Tn Δhly Lmo1291   DP-L7089 This study 
  Δhly Lmo1293   DP-L7090 This study 
  Δhly Lmo1296   DP-L7091 This study 
  Δhly Lmo1366   DP-L7092 This study 
  Δhly Lmo1395   DP-L7093 This study 
  Δhly Lmo1429   DP-L7094 This study 
  Δhly Lmo1499   DP-L7095 This study 
  Δhly Lmo1652   DP-L7096 This study 
  Δhly Lmo1695   DP-L7097 This study 
  Δhly Lmo1742   DP-L7098 This study 
  Δhly Lmo1775   DP-L7099 This study 
  Δhly Lmo1799   DP-L7100 This study 
  Δhly Lmo1835   DP-L7101 This study 
  Δhly Lmo1843   DP-L7102 This study 
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  Δhly Lmo1877   DP-L7103 This study 
  Δhly Lmo1956   DP-L7104 This study 
  Δhly Lmo2027   DP-L7105 This study 
  Δhly Lmo2079   DP-L7106 This study 
  Δhly Lmo2128   DP-L7107 This study 
  Δhly Lmo2229   DP-L7108 This study 
  Δhly Lmo2287   DP-L7109 This study 
  Δhly Lmo2389   DP-L7110 This study 
Δhly lgt::Tn Δhly Lmo2482   DP-L7111 This study 
Δhly lmo2529::Tn Δhly Lmo2529   DP-L7112 This study 
  Δhly Lmo2530   DP-L7113 This study 
  Δhly Lmo2531   DP-L7114 This study 
  Δhly Lmo2581   DP-L7115 This study 
Δhly lmo2634::Tn Δhly Lmo2634   DP-L7116 This study 
  Δhly Lmo2634   DP-L7117 This study 
  Δhly Lmo2641   DP-L7118 This study 
  Δhly Lmo2720   DP-L7119 This study 
  Δhly Lmo2757   DP-L7120 This study 
  Δhly Lmo2760   DP-L7121 This study 
  Δhly Lmo2816   DP-L7122 This study 
  Δhly Lmo2835   DP-L7123 This study 
  Δhly Lmo2835   DP-L7124 This study 
  Δhly Lmo2854   DP-L7125 This study 
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Chapter 4: Concluding Thoughts and Unanswered Questions  
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4.1 Conclusion and outstanding questions 
In this work, we set out to answer a simple question: ‘does LLO in the cytosol have any 
effects on the cell or pathogenesis?’ Despite the simplicity of that question, it has been 
technically challenging to come up with any satisfying answers. We designed a tool hlyfl to 
address that question, and we’ve determined that the answer is yes. LLO in the cytosol can be 
cytotoxic. Like with all findings in science, this result opened the door to so many other 
questions. What type of cytotoxicity does LLO cause? How does LLO-dependent cytotoxicity 
affect pathogenesis? In our search for answers we found even more questions. What type of cell 
death does L. monocytogenes cause, in general? Does L. monocytogenes have a mechanism for 
inhibiting cell death thereby protecting its intracellular niche? Our findings suggest that it might. 
Then there are the even harder questions, the ‘why’ questions. Why does L. monocytogenes 
continue to secrete LLO in the cytosol when it will eventually lead to death of the host cell? Is it 
because LLO is needed for immediate escape from secondary vacuoles? Does LLO in the cytosol 
initiate a host response that contributes to pathogenesis? We hope that hlyfl will allow others to 
continue asking and answering questions about the role of LLO in pathogenesis. 
To complement the work we’ve done on what happens during infections when LLO is 
present, we then investigated what happens when it isn’t. For thirty years it has been known that 
LLO is required for escape from the vacuole and therefore is required for pathogenesis. End of 
story. Not so fast – we’ve also known for a long time that LLO is not required for vacuolar 
escape in HeLa cells. At times this has been written off as an oddity of HeLa cells and at others it 
has been used as a tool to circumvent the requirement for LLO. What hasn’t been asked is: is 
there more to this story? How does L. monocytogenes escape from vacuoles in HeLa cells 
without perforating them with LLO? Are there mammalian host cells in vivo that behave 
similarly? Does it have anything to do with the cancerous properties of HeLa cells? The last two 
questions are increasingly relevant because of the use of L. monocytogenes as an anti-cancer 
therapy. If there is a tumor type that permits L. monocytogenes invasion into the cytosol without 
LLO, perhaps a Δhly strain injected directly into the tumor would be effective and safe.  
In this study, we investigated how the host recognizes and responds to Δhly L. 
monocytogenes infection. When we started this study, we hoped that if we could identify the L. 
monocytogenes component that induces IL-10 we could generate a Δhly L. monocytogenes 
mutant strain that would not induce IL-10 and would therefore be an ideal vaccine delivery 
strain. We found that recognition of nucleic acids by endosomal TLRs and recognition of 
lipoproteins by TLR2, likely following bacteriolysis in the phagosomal compartment, leads to 
production of IL-10 by the host. We identified more than 50 mutations that likely increase L. 
monocytogenes susceptibility to bacteriolysis. Next, we need to identify mutations or strategies 
for manipulating bacteria to lyse less.  
Deleting hly remains the most effective way to attenuate L. monocytogenes in vivo without 
affecting growth outside of cells. It still has potential as a vaccine stain if we can find a way to 
reduce bacteriolysis. On the other hand, that is perhaps an insurmountable challenge. Why not 
use Δhly L. monocytogenes as it is? We, and others, have demonstrated that Δhly L. 
monocytogenes induces potent immunosuppression. Can we take advantage of that to treat 
inflammatory and autoimmune disorders? This possibility has not been adequately explored, and 
there is so much potential.  
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4.2 The Future 
All of the work I’ve done over the past few years has been guided by the hope of finding a 
strain of L. monocytogenes that is safer and/or elicits a stronger adaptive immune response than 
ΔactA. It seems impossible that over the course of 20 years of Listeria research, no one has 
found a strain that works better, yet that continues to be the case. I think that a better vaccine 
strain exists, and that we haven’t found it yet suggests there is still much for us to learn. With L. 
monocytogenes as a tool, there is a future full of advancements in the fields of cell biology, 
immunology, and pathogenesis.    
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Figure 5.1. L. monocytogenes-induced IL-10 and MCP-1 secretion in mice.  
Mice were infected with 108 CFU of Δhly, 105 CFU of ΔactA, or a combination of 108 
CFU of Δhly and 105 CFU of ΔactA. WT C57BL/6J mice (A and E), TLR2-/- (B and F), 
Unc93b13d/3d (C and G), and TLR2-/-TLR5-/-Unc93b13d/3d (D and H) were infected. Serum 
measurements of IL-10 four hours post-infection (A-D) and MCP-1 twenty-four hours 
post-infection (E-H). Data is pooled from two to four independent experiments. Bar 
represents the median. Data analyzed using Holm-Sidak’s Multiple Comparisons test. 
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Figure 5.2. L. monocytogenes-induced IL-6 and IFN-γ secretion in mice.  
Mice were infected with 108 CFU of Δhly, 105 CFU of ΔactA, or a combination of 108 
CFU of Δhly and 105 CFU of ΔactA. WT C57BL/6J mice (A and E), TLR2-/- (B and F), 
Unc93b13d/3d (C and G), and TLR2-/-TLR5-/-Unc93b13d/3d (D and H) were infected. Serum 
measurements of IL-6 (A-D) and IFN-γ four hours post-infection (E-H). Data is pooled 
from two to four independent experiments. Bar represents the median. 
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Figure 5.3. Immune suppression is primarily mediated by endosomal TLR signaling.  
Mice were infected with 108 CFU of Δhly background strains, 105 CFU of ΔactA, or a 
combination of 108 CFU of Δhly background strains and 105 CFU of ΔactA. WT C57BL/6J 
mice (A), TLR2-/- (B), Unc93b13d/3d (C), and TLR2-/-TLR5-/-Unc93b13d/3d (D) were 
infected. Four-to-eight weeks post-vaccination, mice were challenged with 5x105 WT L. 
monocytogenes. CFU from the spleen were enumerated three days post-challenge. Data is 
pooled from two to five independent experiments. Bar represents the median. Data 
analyzed using an unpaired t test.  
 
